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Abstract
Significant uncertainty is known to be present in the internal radia­
tion dose assessments for intakes of uranium compounds. The aim of 
this thesis was to investigate the sources of the uncertainty in the dose 
assessment and in particular the biokinetic models used to describe 
the movement of uranium in the body. A variety of numerical and 
statistical approaches have been used to explore the uncertainty in the 
dose assessments. In particular Bayesian techniques have been applied 
to historical uranium in urine measurements to derive best estimates 
for important biokinetic parameters. Posterior probability distribu­
tions for the important lung solubility parameters have been calcu­
lated from six historical exposure cases. It was shown that improved 
estimates of these parameters can be obtained by sharing the infor­
mation in each of the cases in the Bayesian calculation. Using these 
estimates, the uncertainty in the radiation doses from occupational 
intakes of uranium have been quantified. Lastly, a novel Bayesian ap­
proach to identifying intakes of uranium from bioassay measurements 
has been developed and tested. This Bayesian approach provides a 
number of advantages as it incorporates the uncertainty in the bioas­
say measurements, intake parameters and the bioassay model param­
eters in a coherent way.
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Introduction
1.1 M otivation for this Research
Health physics is the science related to the protection of humans from the harmful 
effects of ionising radiation. Although ionising radiation was discovered over 100 
years ago, uncertainty still remains in the risks to human health from exposures 
to ionising radiation [Preston et ah, 2013]. These uncertainties are particularly 
pronounced in the assessment of the risks from exposures to radioactive material 
that is taken into the body.
Radioactive material can enter the body via inhalation, ingestion, injection or 
absorption. Estimating an internal radiation dose requires the temporal distribu­
tion of the material in the body to be calculated along with the physical radiation 
of the exposed organs or tissues. The complexity in the computer models that are 
used to calculate internal radiation doses, combined with relatively sparse human 
data on the risks from these exposures generates significant uncertainties in the 
calculation of internal doses[CERRIE, 2004].
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Epidemiological studies using historical exposure cases are performed to as­
sess the risks from internal radiation doses[Ritz et ah, 2000][Wakeford, 2004]. 
The estimates of the risks that are calculated from these studies are dependent 
upon the accuracy of the internal radiation doses for the cohort being studied. 
An assessment of the uncertainty on the calculated radiation dose is therefore 
important to enable reliable risk estimates to be made[Stayner et al., 2007].
The results of epidemiological studies into the health effects of ionising radia­
tion are used by the International Commission on Radiological Protection (ICRP) 
to inform their recommendations on how to control the risks to humans from ion­
ising radiation. For internal exposures the ICRP calculates dose coefficients for 
a wide range of radionuclides. These dose coefficients are used to convert an 
intake of activity, typically measured in Bequerels (Bq), into a radiation dose 
that reflects the potential harm to human tissue. The radiation doses calculated 
using the ICRP dose coefficients are point reference values that are used for risk 
assessment and regulatory purposes.
The reliability of the ICRP dose coefficients is dependent on the computer 
models used to calculate radiation doses and on the power of the epidemiological 
studies that are used to estimate the risks. Consideration of the uncertainties in 
the methods used to calculate the dose coefficients is therefore relevant to any 
assessment of the reliability of the dose coefficients [Puncher and Harrison, 2012b].
In this thesis the uncertainties in the application of the ICRP methodology for 
assessing the radiation doses from intakes of uranium nuclides will be assessed. 
Uranium was selected as the radionuclide of interest due to its wide use in the 
nuclear energy and defence sectors. In addition natural uranium is present in 
the environment and therefore intakes of uranium are relevant to all population
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groups. For workers in the nuclear industry the presence of uranium in the envi­
ronment complicates the assessment of occupational doses from uranium intakes. 
In particular the presence of natural uranium can lead to a high number of false 
positive results in an occupational monitoring programme.
1.2 ICRP M ethod for Determining the Internal 
Dose from an Intake of Uranium
To quantify the risks from ionising radiation it is important to define the units 
used for measuring radiation dose. Ionising radiation dose is measured in units 
of Grays (Gy) where 1 Gy is equivalent to 1 J/kg  of radiation energy absorbed. 
This is the fundamental unit of radiation dose and is known as the absorbed dose 
{ D a b s ) -
Calculating the absorbed dose in Gy does not provide a reliable indication of 
the risk of biological harm from that exposure. Ionising radiation that has a high 
ionising density in tissue (e.g. alpha particles) carries a higher risk of biological 
harm to human tissue per Gy than ionising radiation with a low ionisation density 
in human tissue (e.g. photons). The high ionising density from alpha particles 
leads to relatively localised deposition of the energy from the radiation within the 
tissue. Therefore high ionising density radiation is more likely to create double 
strand breaks in the DNA of human cells. A double strand break is where both 
strands of the double helix of the DNA molecule are damaged in the same event. 
Double strand breaks are less likely to be repaired by the cells natural repair 
mechanisms than single strand breaks and are thought to be a precursor for
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developing cancerous cells.
To account for this difference in biological risk, the ICRP assign a weighting 
factor to the radiation dose for different radiation types. The equivalent dose 
measured in Sievert {Sv) is defined as the mean absorbed dose to a particular 
organ or tissue multiplied by the radiation weighting factor for the particular 
radiation type.
P-equiv,T ^  ^'^r * Dabs,T,r (El)
r
Where:
Hequiv,T IS the equivalent dose (Sv)
Wr is the radiation weighting factor for the type of ionising radiation 
Dabs,T,r IS the mean absorbed dose in a particular organ or tissue (T)
The radiation weighting factors are not fundamental quantities but rather 
represent the best estimates of comparative risk for different radiation types. 
The radiation weighting factors recommended in ICRP publication 103[ICRP, 
2013] are shown in table 1.1.
u{x) = <
2.5 +  18.2e-M^")]'/G Eyz < IMeU
5 +  iM eV  < E n <  50MeV  (12)
2.5 +  En > 50MeV
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Table 1.1: Radiation Weighting Factors from ICRP publication 103
[ICRP, 2013]
Ionising Radiation Type Radiation Weighting Factor, Wr
Photons, all energies 1
Electrons, muons, all energies 1
Protons and charged pions 2
Alpha particles, heavy ions, fis­ 20
sion fragments
Neutrons A continuous function of neutron energy
shown in equation 1.2
Another important factor in estimating the risk from a particular exposure 
to ionising radiation is the organs in the human body that are being irradiated. 
It is known from animal experiments and human epidemiological studies that 
different organs in the body have different radiosensitivities to ionising radiation. 
Therefore the ICRP have a derived quantity called the effective dose that is 
calculated by weighting the equivalent dose with tissue weighting factors that 
provide the best estimate of the relative radiosensitivity of the organs and tissues 
in the body. The tissue weighting factors recommended in ICRP publication 
103[ICRP, 2013] are shown in table 1.2.
(1.3)
t r
Where:
Heff  is the effective dose (Sv) 
Wt is the tissue weighting factor
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Wr is the radiation weighting factor for the type of ionising radiation 
Dabs,T,r is the mean absorbed dose in a particular organ or tissue (T)
It is worth noting that the unit of ionising radiation dose is the Sievert for both 
equivalent and effective doses. This reflects that both equivalent and effective dose 
are risk quantities rather than physical units.
Table 1.2: Tissue Weighting Factors from ICRP publication 103
Tissue Tissue Weighting Factor, Wt
Bone marrow (red), colon, lungs. 0.12
stomach, breast, remainder tis­
sues
Gonads 0.08
Bladder, oesophagus, liver, thy­ 0.04
roid
Bone surface, brain, salivary 0.01
glands, skin
Calculating radiation doses from radionuclides that are taken into the body is 
more complicated than calculating doses from an external source of radiation; this 
is due to the radiation exposure being protracted, with the total time of exposure 
depending on the biokinetics of the radionuclide in the body and the physical half 
life of the radionuclide. Therefore, by convention when internal radiation doses 
are calculated the dose is integrated over the fifty years following an exposure.
'50 
'0
P-eff — I  ^   ^^   ^'^t * * Dabs^t (1.4)
t r
Where:
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Heff  is the committed effective dose (Sv) 
t is the time in years since the initial exposure 
Wt is the tissue weighting factor
Wr is the radiation weighting factor fr the type of ionising radiation 
Dabs,T,r Is the mean absorbed dose rate in a particular organ or tissue (T)
For children the dose is integrated up to the age of seventy years old. This 
is to ensure that the calculated dose reflects the lifetime risk from a particular 
exposure. Radiation doses that have been integrated in this way are called com­
mitted equivalent or committed effective doses. In this thesis when equivalent or 
effective doses are discussed in relation to internal exposures it can be assumed 
that they refer to committed equivalent or committed effective doses.
An overview of the assessment method used to calculate effective dose is shown 
in figure 1.1. For a given intake of uranium, the ICRP have published biokinetic 
models that describe the time dependent concentration of uranium in the body. 
These biokinetic models represent key organs and tissues as compartments with 
rate parameters describing the movement of uranium into and out of each com­
partment. The biokinetic models for uranium are described in detail in chapter 
2 .
After the distribution of uranium in the body has been established using 
the biokinetic models, dosimetric models are applied that calculate the mean ab­
sorbed dose for the organs and tissues that are being irradiated. For the purposes 
of this thesis the dosimetric models are assumed to be accurate.
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Estimated Intake (Bq)
Mean absorbed dose (Gy)
Biokinetic and Dosimetric Model
Radiation weighting factor, w.
Equivalent Dose (Sv)
-^--------------------------- Tissue weighting factor, w^
Effective Dose (Sv)
Figure 1.1: Method for calculating the effective dose for a known intake
In figure 1.1 the size of the intake of uranium is known precisely. This type of 
assessment is termed a prospective dose assessment and in the nuclear industry 
would be used for risk assessments for planned activities.
For accidental exposures to uranium the intake will not be known precisely 
and instead will have to be inferred from any area monitoring taken at the time 
of a suspected intake and from bioassay samples taken from the individual who 
is thought to have been exposed. For uranium exposures bioassay samples can 
include urine and faecal samples being taken from the exposed person.
Figure 1.2 shows how the biokinetic models are applied to estimate the activity 
from the bioassay measurement. They are then applied again to calculate the 
effective dose due to that exposure.
The research aims of this study focus on the biokinetic models used in the cal­
culation of internal doses. The dosimetric model and the validity of the weighting 
factors is beyond the scope of this thesis. At this point it is worth noting that 
effective doses are calculated for a reference person in a particular cohort and do 
not represent risk to any particular individual.
Bioassay Measurement (Bq)
Estimated Intake (Bq)
Mean absorbed dose (Gy)
Equivalent Dose (Sv)
Effective Dose (Sv)
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Biokinetic Model
Biokinetic and Dosimetric Model
Radiation weighting factor, w.
Tissue weighting factor, w^
Figure 1.2: Method for calculating the effective dose for an unknown intake
1.3 Uncertainty in the Assessment of Radiation
Doses
A number of computational uncertainty studies have been undertaken to in­
vestigate the uncertainty in the assessment of radiation doses [Puncher et ah, 
2012][Apostoaei and Miller, 2004][Bouville et al., 1994]. Assigning probability 
distributions to the biokinetic model parameters to reflect the quality and quan­
tity of data available on each parameter is a common approach. There are any 
number of probability distributions that can be used to represent the uncertainty 
in particular model parameters. It is however important that the chosen distri­
bution reflects plausible ranges for each parameter. Commonly used probability 
distributions for this type of analysis include:
Chapter 1
Uniform or Flat D istribution
Here all of the possible values between a maximum and a minimum value are 
seen as equally likely. This distribution may be used where little information 
is available for a particular parameter In this thesis a uniform probability 
distribution will be described using the nomenclature U(min, max). Figure
1.3 shows the probability distribution U(0,1).
0.025
0.02
0.015
P(x)
0.01
0.005
0.2 0.4 0.6
X
0.8 1.2
Figure 1.3: Uniform distribution with a minimum of 0 and a maximimum of 1
Norm al or Gaussian D istribution
A normal distribution is a symmetrical probability distribution where the 
mean, median and mode all have the same value. The normal probability 
distribution is described in equation 1.5.
10
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p(x) = (1.5)
In this thesis a normal probability distribution will be described using the 
nomenclature N(mean, standard deviation). Figure 1.4 shows the probabil­
ity distribution N(20,5).
0.09
0.08
0.07
0.05
0.05
0.04
0.03
0.02
0.01
150 5 10 20 25 30 35 40
Figure 1.4: Normal probability distribution mean 20 and standard deviation 5
Lognormal D istribution
A lognormal distribution is a positively skewed probability distribution. 
This is a popular distribution for this type of analysis as experimental re­
sults suggest that many of the parameters of interest follow an approximate 
lognormal distribution. The lognormal probability distribution is described 
in equation 1.6.
11
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p(x) =
Trax
(1.6)
In this thesis a lognormal probability distribution will be described using 
the nomenclature LN(median, geometric standard deviation). Figure 1.5 
shows the probability distribution LN(10,3).
0.07
0 06
0 05
0 04
X) 030
0
0
X
Figure 1.5: Lognormal probability distribution
To propagate the uncertainty in a particular parameter into the calculation of 
the effective dose a Monte Carlo technique can be used to sample model param­
eters from their assigned probability distributions. An effective dose can then 
be calculated for each vector of sampled parameters. This method provides a 
distribution of effective doses and has been applied to a wide range of nuclides 
and models.
12
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As the effective dose is a risk quantity rather than a physical quantity it is 
important to understand that the derived uncertainty reflects the uncertainty 
on the radiation dose to a reference person of the population of interest. This 
reference person is intended to represent an average member of a a particular 
population. The quantified uncertainty on the effective dose is therefore an indi­
cation of the reliability of the radiation protection system rather than implying 
an uncertainty on a radiation dose calculated for an individual. The meaning of 
the uncertainty in the calculated effective dose is discussed in detail by Puncher 
and Harrison[Puncher and Harrison, 2012b].
For situations where the intake is unknown and bioassay measurements have 
been taken, Bayesian techniques have proved a useful statistical method for the 
assessment of uncertainty in calculated doses [Miller et ah, 2000] [Little et ah, 
2007][Puncher and Birchall, 2008][James et ah, 2008]. Bayesian methods enable 
the uncertainties in the biokinetic model parameters, described by their assigned 
probability distributions, to be combined with the uncertainties in the measured 
data to estimate the overall uncertainty of the calculated dose.
For uranium bioassay measurements, identifying an occupational intake is con­
founded by the presence of background uranium due to environmental intakes of 
uranium. The Bayesian approach allows this additional uncertainty to be incor­
porated with the biokinetic model uncertainty and the measurement uncertainty. 
A brief description of Bayes theorem is provided below.
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1.3.1 Overview of Bayes Theorem
Bayes theorem was developed by the eighteenth century mathematician and the­
ologian the Rev Thomas Bayes[Bayes and Price, 1763]. Formally Bayes theorem 
is derived from probability theory and is shown in equation 1.7.
Where:
P{X\M)  is read as the probability of X given M and is called the posterior 
distribution
P{M\X)  is called the likelihood function
P{X)  is the prior probability of X
Bayes theorem is a method of formally combining prior knowledge about a 
particular parameter or hypothesis, with the observed data. The prior knowledge 
is represented by a prior probability distribution on X. Now X is frequently a 
vector of model parameters and therefore to solve for a particular parameter 
the marginal probability distribution for the parameter of interest needs to be 
calculated. The integration required to generate the marginal distribution for a 
particular parameter is normally multidimensional and numerical methods are 
required to solve the integral.
The application of Bayesian methods to bioassay measurements has been 
extensively developed at the Los Alamos National Laboratory in the United
14
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States using Markov Chain Monte Carlo computer methods to solve the nec­
essary integrals [Miller et a l, 2002]. This work was extended by Puncher and 
Birchall [Puncher and Birchall, 2008] to consider all model parameters and an 
alternative computational technique called the Welmos method was developed.
Davesne[Davesne, 2010] reported an alternative approach based on using dis­
crete values rather than continuous distributions to represent parameter uncer­
tainty. While this approach reduces the computation power required it does not 
represent the most complete solution.
In this thesis both a modified version of the Welmos method and MCMC 
methods are used to apply Bayesian methods to bioassay measurements from 
uranium exposures.
1.4 Research Objective
The major research objective of this project is to consider the impact of uncer­
tainty in the model parameters of the biokinetic models on the calculation of 
radiation dose to an individual from an exposure to uranium isotopes. In partic­
ular this work will focus on:
1. Obtaining the best estimates for the model parameters used for calculating 
internal doses from uranium.
2. Estimating the uncertainty in the dose coefficient for occupational exposures 
to uranium.
3. Applying Bayesian techniques to the practical problem of identifying when 
occupational intakes of uranium have occurred and estimating doses from
15
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bioassay measurements.
1.5 Thesis Overview
This thesis presents an application of established computational uncertainty anal­
ysis techniques to uranium dose assessments. In addition a novel approach to the 
problem of identifying occupational uranium exposures from bioassay measure­
ments is developed and tested. A brief overview of the core chapters of this thesis 
is provided below.
Chapter 2 - Sensitivity Analysis of the Uranium Biokinetic Models
In chapter 2 an overview of the biokinetic models used in calculating radia­
tion doses from uranium exposures is provided. The results of a sensitivity 
analysis to establish the important parameters for calculating occupational 
doses from uranium exposures are also reported. The work in this chapter 
contributed to the work published by Puncher and Burt [Puncher and Burt, 
2013^
Chapter 3 - Estimating Uranium Lung Solubility Parameters from Historical 
Bioassay Data
In chapter 3 historical bioassay measurements from uranium exposures are 
analysed using a Bayesian statistical technique to provide improved esti­
mates of the important model parameters. Markov Chain Monte Carlo 
(MCMC) methods are used to numerically solve the integrals required. Im­
proved estimates for the lung solubility parameters in the ICRP HRTM are 
generated.
16
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Chapter 4 - Uncertainty in ICRP Dose Coefficients for Uranium
In chapter 4 the uncertainty in the effective dose coefficient for occupational 
exposures to uranium is estimated. Important biokinetic model parameters 
are represented by probability distributions that represent the current state 
of knowledge on those parameters. The results for both prospective and 
retrospective dose calculations were compared.
Chapter 5 - A Bayesian Method For Identifying Occupational Intakes For Ura­
nium Workers
In chapter 5 a novel Bayesian method is developed to assist in identifying 
occupational uranium intakes from bioassay measurements. This method 
considers uncertainties on the model parameters, the bioassay measure­
ment and environmental intakes. Part of the work here was presented as a 
poster at the 13th International Radiation Protection Associated Interna­
tional Congress 2012.
17
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Sensitivity Analysis of the  
Uranium Biokinetic M odels
The ICRP biokinetic models for uranium are used to calculate the effective dose 
following an intake of uranium. As different organs are known to have different 
sensitivities to ionising radiation, the concentration of uranium in the different 
organs will have a significant impact on the calculated dose. As shown in figure 
1.2, for retrospective dose estimates from bioassay, the biokinetic models are 
applied twice:
F irst To estimate the intake from a bioassay measurement.
Second To calculate the effective dose from the estimated intake.
Uncertainty in the biokinetic models is therefore an important element in 
calculating doses from occupational exposures to uranium. The biokinetic models 
can also be used to determine the concentration of uranium for assessing the 
risks from chemical toxicity. In particular uranium is known to be harmful the
18
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kidneys and therefore estimating the concentration in the kidney is important for 
toxicology studies into uranium [Bryant , 2014].
The ICRP publish general models for the human respiratory tract and the 
human alimentary tract that are applied to intakes of radioactive particles; in 
addition there are nuclide specific models for the behaviour of nuclides upon 
absorption into the blood stream. The biokinetic models divide the body into 
a number of compartments that represent organs, tissues and other biological 
systems.
The compartments have associated kinetic rates for activity entering or leav­
ing each compartment. These are estimated rates that are typically based on 
data from exposed human individuals and animal experiments [Leggett, 1994]. 
The models produce a series of first order differential equations to represent the 
movement of material in the human body. A simple two compartment model is 
shown in figure 2.1.
•12
Figure 2.1: Simple two compartment model
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For the simple two compartment system shown in figure 2.1, the location of 
the nuclides can be described by:
dt
— k \ ^ 2 N i { t )  — k 2 N 2 { t )  — k 2 , i N 2 { t )  (2 .2)dt
Where:
Ni{t) = number of atoms in compartment i at time t
kij = rate constant describing movement of atoms from compartment i to com­
partment j
ki = rate constant describing physical and radiological removal of atoms from 
compartment i
The compartment models can be solved numerically to estimate the movement 
of radionuclides through the body. One source of uncertainty in the output of the 
model is in the parameter values chosen to represent the rate constants. The rate 
constants cannot be determined directly and therefore uncertainty is introduced 
in the process of inferring the values for each parameter from related data.
In the first part of this chapter the biokinetic models used for calculating 
the effective dose from intakes of uranium are described. The second part of 
this chapter describes a sensitivity analysis to determine the biokinetic model 
parameters that have the largest effect on the calculation of effective dose.
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2.1 Overview of Uranium Biokinetic M odels
2.1.1 Human Respiratory Tract M odel
The human respiratory tract model (HRTM) recommended by the ICRP was 
published in ICRP publication 66 [ICRP, 1994]. It built upon the previous res­
piratory tract model that was considered too simplistic a representation due to 
significant variations in the relative radiation sensitivity in the different parts of 
the respiratory tract that were not accounted for in previous models[ICRP, 1979]. 
The complexity of the model refiects the importance of the respiratory tract in 
determining dose from intakes of radionuclides. Figure 2.2 shows the anatomy of 
the respiratory tract and how the different regions are defined for the purpose of 
calculating radiation doses.
The extra thoracic region conditions the air before it gets to the deeper lung 
with the inhaled air being warmed and moistened and larger particulate are 
removed. The bronchial region consists of the trachea and the bronchi and splits 
the inhaled air between the two lungs. Further removal of larger particulate by 
impaction, sedimentation and/or diffusion occurs in the bronchial region. The 
bronchiolar region is made up of the bronchioles in generations 9 to 15. The 
airways beyond the bronchiolar region are the alveoli, where gaseous exchange 
takes place. The alveolar-interstitial region contains the alveoli that facilitate 
gaseous exchange.
Figure 2.3 shows the compartmental model of the respiratory tract. The num­
bers next to the arrows represent the removal constants for the model and are in 
units of day“ .^ The removal of material from each compartment is represented by 
a summation of exponential terms. The removal constant from one compartment
2 1
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Figure 2.2: Anatomical view of the human respiratory tract (from ICRP publi­
cation 66 [ICRP, 1994]
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to another is calculated by dividing the natural logarithm of two by the total half 
time for the movement of material between each compartment.
Removal Constant = ln{2)t: (2.3)
This is analogous to the traditional decay constant used for radioactive half 
life calculations. As the material is radioactive the material will also be removed 
due to radioactive decay.
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Figure 2.3: Human respiratory tract model (from ICRP publication 66). The 
extrathoracic region includes the anterior (ETl) and posterior (ET2) nasal pas­
sages. The thoracic region includes the bronchial airways (BB), the bronchiolar 
airways (bb) and the alveoli region (AI). The material sequestered in the airway 
wall may be transferred to the lymphatic system through the lymph nodes (LN).
The amount of material that is deposited in the different regions of the respira­
tory tract is dependent on the particle size of the inhaled radionuclide (see figure
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2.4). Particles that have an aerodynamic median activity diameter (AMAD) of 
greater than Ijim  are mostly deposited in the upper regions of the respiratory 
tract and have significantly faster removal rates. Particles that deposit in the 
lower region of the lung are likely to be retained for longer and therefore have an 
increased contribution to the total effective dose.
The absorption of the material from the respiratory tract into the blood stream 
is modelled as a two stage process where the particles are deposited before being 
dissolved into the body fluids. Two alternative methods for representing the 
uptake of material into the blood stream were proposed in ICRP publication 66.
The systems are similar with figure 2.5a proposing that there is a component 
of the particle deposited that will dissolve slowly, whereas figure 2.5b proposes 
that following deposition a fraction of the deposited particulate is changed from 
the initial state into a state with different removal constants. In this thesis the 
process shown in figure 2.5a will be used.
In addition to the removal of material from the respiratory tract via absorption 
there is also a competing physical removal process via the mucocilary escalator. 
This process is shown in figure 2.3 as material moves between compartments via 
particle transport. Material that is transported into the extra thoracic region 
may then be transferred out of the respiratory tract into the alimentary tract or 
out of the body.
2.1.2 Human Alimentary Tract M odel
The human alimentary tract model (HATM) published in ICRP publication 
30[ICRP, 1979] will be used throughout this thesis. This model was developed by
24
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Figure 2.4: Fractional deposition in the regions of the respiratory tract for differ­
ent particle sizes (from ICRP publication 66). AMAD - The particle size where 
50% of the activity is in particles smaller than the AMAD. AMTD - The activity 
median thermodynamic diameter (AMTD) is used for small particles where diffu­
sion dominates the motion of the particles. AMTD is also defined as the particle 
size where 50% of the activity is in particles smaller than the AMTD.
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Figure 2.5: Mathematical models describing deposition and absorption in the 
HRTM (from ICRP publication 66). In (a) a fraction of the particles dissolve 
rapidly {fr) at a rate Sr and the remaining particles dissolve at a slower rate (sg). 
In (b) the particles are transformed to a different state at a rate Spt. The particles 
in the initial state dissolve at a rate Sp and the particles in the transformed state 
dissolve at a rate St. In both models a fraction of the particles become bound to 
tissue (fb) in the HRTM and is then transferred to body fluids at a rate s .^
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Dolphin and Eve [Dolphin and Eve, 1966] and represents the human alimentary 
tract with four compartments; the stomach, small intestine, upper large intestine 
and lower large intestine.
ngestion
Feces
ULl
espîratory
Tract
00
Figure 2.6: Human alimentary tract model (from ICRP publication 30[ICRP, 
1979]). The stomach (St), small intestine (SI), upper large intestine (ULI) and 
lower large intestine (LLI) are all included in the HATM.
The general structure of the human alimentary tract is shown in figure 2.6. 
The model published in ICRP 30 was designed to reproduce the mean transfer 
times for material passing through, and out of, the alimentary tract. Absorp­
tion of nuclides was assumed to occur only in the small intestine and absorption 
fractions (fl values) were assigned for nuclides depending on their chemical form.
An updated HATM was produced in 2007 to bring the treatment of radionu-
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Figure 2.7: Updated human alimentary tract model (from ICRP publication 
100[ICRP, 2007])
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elides in the alimentary tract in line with modern understanding of the physiology 
of the tract [ICRP, 2007]. In addition, the new model allowed the calculation of 
doses to known sensitive cells in different regions of the alimentary tract. The new 
model added more compartments as shown in figure 2.7 and brings the alimentary 
tract model in line with the complexity of the HRTM.
For the purposes of this thesis the complexity of the new model for the al­
imentary tract is not required. In particular the recycling of uranium material 
in the alimentary tract and the different rates of absorption applied to different 
sections of the alimentary tract are not required. It is of use when determining 
doses to particular compartments within the alimentary tract but for an overall 
uncertainty analysis of the effective doses for uranium intakes it is not required.
2.1.3 Uranium System ic M odel
The uranium systemic model published by the ICRP in publication 69[ICRP, 
1995a] was a simplified version of a model proposed by Leggett [Leggett, 1994]. 
It was based on the framework developed for alkaline earth metals as uranium 
was also seen to have an affinity to reside in bone tissue. The model param­
eters were primarily estimated using the results from three hospital studies on 
the distribution of uranium following an intake[Struxness et ah, 1956][Bassett 
et al., 1948][Terepka et al., 1964]. The participants in these studies were not 
healthy adults which introduced significant uncertainty as to whether the rates 
in the model reflect the mean values for the population. In addition to the three 
hospital studies the transfer rates for each compartment were based on the re­
tention fractions seen in post-mortem measurements of exposed individuals, data
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from animal studies, and direct measurements of uranium in blood, urine and 
faeces. Physiological processes involved that are well characterised were incor­
porated into the establishment of the transfer rates. While there is uncertainty 
on whether the transfer rates chosen represent a reasonable approximation to 
the central value of the population, the important aspect of the model is that it 
reproduces the distribution of uranium seen in the body rather than individual 
rates being known precisely. The general features of the uranium systemic model 
are shown in figure 2.8.
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Figure 2.8: Uranium systemic model (from ICRP publication 69[ICRP, 1995a]
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Table 2.1: Default transfer rates in the ICRP uranium systemic model
Path Transfer Rates d~^
Plasma to STO 10.5
Plasma to RBC 0.245
Plasma to Urinary Bladder Contents 15.43
Plasma to Urinary Path 2.94
Plasma to Other Kidney Tissue 0.0122
Plasma to ULI Contents 0.122
Plasma to Liver 1 0.367
Plasma to STl 1.63
Plasma to ST2 0.0735
Plasma to Trabecular Surfaces 2.04
Plasma to Cortical Surfaces 1.63
STO to Plasma 8.32
RBC to Plasma 0.347
Other Kidney Tissue to Plasma 0.00038
Liver 1 to Plasma 0.092
Liver 2 to Plasma 0.00019
STl to Plasma 0.0347
ST2 to Plasma 0.000019
Bone Surfaces to Plasma 0.0693
Non-exchangeable Trabecular Volume to Plasma 0.000493
Non-exchangeable Cortical Volume to Plasma 0.0000821
Urinary Path to Bladder Urine 0.099
Liver 1 to Liver 2 0.00693
Bone Surfaces to Exchangeable Volume 0.0693
Exchangeable Bone Volume to Surfaces 0.0173
Exchangeable Bone Volume to Non-exchangeable Volume 0.00578
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2.2 Sensitivity Analysis of the Uranium Bioki­
netic Models
2.2.1 Introduction
The described biokinetic models have a large number of parameters each of which 
will have an impact on the calculated effective dose for a given intake. A sen­
sitivity analysis of the biokinetic models quantifies the effect on the calculated 
effective dose due to a change in each model parameter. This will identify the 
important parameters for calculating the effective dose.
A previous sensitivity analysis of the uranium systemic model was undertaken 
by Harrison et al [Harrison et al.] using the sensitivity analysis method described 
by Khursheed and Fell[Khursheed and Fell, 1997]. Their study focussed on the 
sensitivity of the calculated activity in particular model compartments to the 
systemic model parameters. This analysis highlighted the important parameters 
in the systemic model for identifying intakes of uranium from bioassay measure­
ments. The identified parameters however, may not necessarily be the parameters 
that have a significant effect on the calculation of the effective dose as required 
here.
Puncher and Harrison [Puncher and Harrison, 2012a] proposed a simplified 
sensitivity analysis approach by replacing the activity in individual model com­
partments with the calculated effective dose as the sensitivity analysis end-point. 
In their method, model parameters are changed individually by a given fraction 
and the observed change in the calculated effective dose is recorded. This enables 
the sensitivity analysis to be done efficiently, and it relates the model parameters
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directly to the effective dose.
In this sensitivity analysis, the approach of Puncher and Harrison[Puncher 
and Harrison, 2012a] is applied to the uranium biokinetic models to determine 
the important parameters for calculation of the effective dose. The analysis will be 
repeated for three different uranium isotopes and to determine
if there is any difference between the biokinetic model sensitivity for each isotope.
2.3 M ethod
The sensitivity analysis approach described by Puncher and Harrison [Puncher 
and Harrison, 2012a] was applied to the ICRP uranium biokinetic models to 
identify the model parameters that have the greatest effect on the calculation of 
the effective dose for intakes of uranium. In this method a sensitivity coefficient, 
Sij^ for a particular parameter in the biokinetic model is calculated using equation
2.4.
Where:
Sij is the sensitivity coefficient for the rate from compartment i to j  in the 
biokinetic model
\ij  is the transfer rate from compartment i to j  in the uranium biokinetic model 
AAÿ is the change in the transfer rate from compartment i to j  
D is the effective dose calculated by the model
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AD is the observed change in the effective dose coefficient produced by the 
change in the transfer rate
The ratio ^  was set at 0.01, 0.05 and 0.10 for the sensitivity analysis under­
taken here. The sensitivity analysis was carried out for intakes by ingestion and 
inhalation and was repeated for three different isotopes of uranium: 
and The analysis was carried out for prospective and retrospective dose
calculations to see how the model parameters effect both calculations of effective 
dose.
For each analysis the uranium systemic model was used with the ICRP Pub­
lication 60[ICRP, 1991] radiation and tissue weighting factors to calculate the 
effective dose coefficient. For an intake by ingestion the HATM from ICRP pub­
lication 30[ICRP, 1979] was included to enable the calculation of the effective 
dose. The absorption parameter (fl) that governs the transfer of material from 
the alimentary tract to the blood was included in the sensitivity analysis.
Similarly for intake by inhalation, the HRTM from ICRP publication 66[ICRP, 
1994] was coupled with the HATM and the uranium systemic model to calculate 
the effective dose. The model parameters included in the sensitivity analysis for 
ingestion included all of the systemic parameters in table 2.1 and the absorption 
parameter, fl. For the inhalation sensitivity analysis the parameters in table 2.2 
were included, as well as the parameters in the ingestion analysis. The HRTM 
parameters included in the sensitivity analysis were:
AMAD
The activity median aerodynamic diameter (AMAD) is the size of particle 
in a radioactive aerosol where 50% of the activity is in particles smaller
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than the AM AD.
Sigma G
This model parameter describes the dispersion of the aerosol.
Particle Density
The particle density describes the density of the aerosol typically measured 
in g/cm^.
Shape Factor
The shape factor is a parameter that impacts on the particle motion in the 
respiratory tract.
Particle Transport
The physical removal of particles from the respiratory tract was assumed 
to be correlated in each compartment and they were varied together using 
the particle transport parameter.
f r
The fraction of inhaled particles that are absorbed rapidly.
Sj-
The rate of absorption of the fraction that is absorbed rapidly.
The rate of absorption of the fraction that is absorbed slowly.
ETl Aero
Scaling coefficient to determine the fraction of material deposited in the 
region ETl by aerodynamic deposition.
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ETl Thermo
Scaling coefficient to determine the fraction of material deposited in the 
region ETl by thermodynamic deposition.
ET2 Aero
Scaling coefficient to determine the fraction of material deposited in the 
region ET2 by aerodynamic deposition.
ET2 Thermo
Scaling coefficient to determine the fraction of material deposited in the 
region ET2 by thermodynamic deposition.
Breathing Rate
The breathing rate of an average member of the population.
Fractional Nose Breathing
The fraction of inhaled material that is breathed through the nose.
The sensitivity analysis was performed using the IMBA Uncertainty Analyser 
software [Puncher and Birchall, 2008] developed at the Health Protection Agency 
(HPA). This software directly calls the subroutines of the dosimetry code IMBA 
Professional Plus [Birchall et al., 2007] to solve the required biokinetic and dosi­
metric models. The code performed the following steps:
1. The intake scenario was set in IMBA (including isotope, intake type and 
required biokinetic models).
2. The model parameters to be included in the sensitivity analysis were chosen 
in the IMBA Uncertainty Analyser.
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Table 2.2: Biokinetic model parameters included in the sensitivity analysis for 
intakes via inhalation
Model Parameter Default Parameter Values (ICRP Type M)
AMAD 5
Sigma G 2.5
Particle density 3
Shape factor 1.5
Particle transport 1
f r 9.9955 X 10-^
S f 1 X 10^
S s 5 X 10-^
ETl Aero 3.0 X 10-4
ETl Thermo 18
ET2 Aero 5ffi )< icr-5
ET2 Thermo 15.1
Breathing rate 1.2
Fractional Nose Breathing 1
3. The percentage change for each parameter was set at 1% above and below 
the initial value.
4. The model parameters to be varied were selected one at a time and the effec­
tive dose was calculated for the initial parameter value and the parameter 
value ±1%.
5. The sensitivity coefficient was calculated for each parameter using equation
2.4. The greater absolute sensitivity coefficient seen when the parameter 
was altered by ±1% was recorded.
The analysis was repeated for changes of ±5% and ±10% in the model pa­
rameters.
For the retrospective sensitivity analysis, a uranium in urine measurement was 
set in IMBA rather than an intake value. A 1 mBq uranium in urine measurement
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taken at the mid point of a 90 day sampling period was used for this calculation 
and a ±1% change for each parameter. The code was run in the same way as for 
the prospective analysis.
As noted by Puncher and Harrison[Puncher and Harrison, 2012a], the method 
applied here does not identify any of the potential synergistic effects between 
model parameters, however the purpose of this sensitivity analysis was to identify 
the important parameters and it is unlikely that parameters that have only a 
negligible impact when varied individually will have a significant effect on the 
overall effective dose coefficient.
2.4 Results
The aim of the sensitivity analysis was to identify the important parameters in the 
uranium biokinetic models for calculating the effective dose. Previous sensitivity 
analyses for depleted uranium exposures identified lung solubility parameters and 
the systemic rates to and from the skeleton/liver/kidney[Puncher et al., 2008] as 
important parameters. This study considered a wider range of biokinetic model 
parameters and their effect on prospective and retrospective dose calculations. 
The analysis was also repeated for the three main isotopes of uranium however 
it is worth noting that no significant difference was seen in the results of the 
sensitivity analysis for the different isotopes.
In general, the systemic model parameters highlighted as being significant 
for the calculation of effective dose were similar to those identified by Harrison 
et al [Harrison et al.] for identifying intakes from bioassay measurements. In 
particular the transfer rates from blood plasma to bladder and those describing
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the exchange between blood plasma and skeleton are important parameters. In 
addition to the parameters identified in both studies, the transfer of material from 
blood plasma to long term retention in massive soft tissue (ST2 compartment) 
was also seen to be an important parameter in the calculation of the effective 
dose coefficient.
The calculated sensitivity coefficients for intakes by ingestion are shown in 
tables 2.3 - 2.5. For intakes by ingestion the absorption coefficient from the 
alimentary tract to the blood (fl) produced a higher sensitivity coefficient than 
any of the systemic model parameters. This is in agreement with the results of a 
sensitivity analysis carried out by Puncher and Harrison[Puncher and Harrison, 
2012a] for ingestion of plutonium and americium that identified the fl absorption 
parameter as the most important model parameter for those actinides.
In tables 2.7 - 2.9 it can be seen that for an intake by inhalation, changes in the 
systemic parameters have only a small effect on the calculated dose coefficient; 
this was also seen by Puncher et al [Puncher et a l, 2008] when they undertook 
an uncertainty analysis of doses following an inhalation of depleted uranium. 
The absorption parameter associated with long term retention in the lung, Sg, 
produced the largest sensitivity coefficient for intakes via inhalation.
The results of the sensitivity analysis for the retrospective calculation of ef­
fective dose is shown in tables 2.6 and 2.10. The solubility parameter related to 
the long term retention of uranium in the lung was shown to be the dominant 
parameter for estimating the effective dose from bioassay measurements.
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Table 2.3: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via ingestion for a 1% change in each parameter
Model Parameter 234[f 235 JJ
fl (1959 0.946 (1956
Blood to urinary bladder -0.756 -0.747 -0.754
Blood to ST2 0.504 0JW6 0.500
Blood to TS 0.197 0.195 (1202
TS to Blood -0.156 -0.156 -0.160
TVNE to Blood -0.142 -0.142 -0.147
Blood to Urinary Path -0.144 -0.142 -0.143
TS to TVE 0.116 0.116 0.121
Blood to Liver 1 0.108 0.107 0.107
Liver 1 to Blood -0.100 -0.099 -0.099
Table 2.4: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via ingestion for a 5% change in each parameter
Model Parameter 234fy 235[f 238(7
fl 0.929 (1918 (1928
Blood to urinary bladder -0.732 -0.723 -0.731
Blood to ST2 0.505 0.497 0.500
Blood to TS 0.196 0.195 0.200
TS to Blood -0.150 -0.150 -0.154
TVNE to Blood -0.136 -0.135 -0.140
Blood to Urinary Path -0.143 -0.141 -0.143
TS to TVE 0.114 0.114 0.118
Blood to Liver 1 0.109 0.107 0.108
Liver 1 to Blood -0.097 -0.095 -0.096
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Table 2.5: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via ingestion for a 10% change in each parameter
Model Parameter 234fy 235^ 238 jj
fl 0.929 0.917 0.927
Blood to urinary bladder -0.703 -0.695 -0.702
Blood to ST2 0.504 0.497 0.500
Blood to TS 0.196 0.195 0.200
TS to Blood -0.145 -0.144 -0.148
TVNE to Blood -0.129 -0.129 -0.134
Blood to Urinary Path -0.141 -0.140 -0.141
TS to TVE 0.113 0.113 0.117
Blood to Liver 1 0.109 0.107 0.108
Liver 1 to Blood -0.092 -0.091 -0.092
Table 2.6: Sensitivity coefficients for retrospective calculation of effective dose 
from intakes of uranium isotopes via ingestion for a 1% change in each parameter
Model Parameter 234^ 235 J J 238 J J
Blood to ST2 0.513 (1508 0.508
Urinary path to urinary bladder 0.482 0.482 0.481
Blood to STl -0.379 -0.378 -0.379
TVE to TS -0.222 -0.221 -0.226
TS to TVE 0.201 0.202 0.205
Blood to Urinary Path -0.192 -0.189 -0.191
TS to Blood -0.167 -0.165 -0.170
CVE to OS -0.145 -0.144 -0.144
TVNE to Blood -0.142 -0.142 -0.147
OS to CVE 0.119 0.121 0.120
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Table 2.7: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via inhalation for a 1% change in each parameter
Model Parameter 2 3 4 ^ 2 3 5 ^ 2 3 8 ( 7
Fractional nose deposition -2.020 -1.994 -1.985
-0.585 -0.584 -0.556
AMAD -0.402 -0.402 -0.355
Breathing rate -0.393 -0.396 -0.401
Particle transport -0.325 -0.326 -0.352
ET2 aero -0.238 -0^85 -0.208
Sigma G -0.163 -0.160 -0.246
Blood to urinary bladder -0.079 -0.080 -0.077
f r -0.064 -0.063 -0.068
ETl aero -0.06 -0.06 -0.05
Table 2.8: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via inhalation for a 5% change in each parameter
Model Parameter 2 3 4 ( 7 2 3 5  J J 2 3 8  J J
Fractional nose deposition -2.017 -1.991 -1^82
5s -0.567 -0.566 -0.565
AMAD -0.399 -0.399 -0.403
Breathing rate -0.410 -0.412 -0.417
Particle transport -0.318 -0.319 -0.319
ET2 aero -0.233 -0.230 -0.230
Sigma G -0.160 -0.158 -0.155
Blood to urinary bladder -0.077 -0.077 -0.079
f r -0.064 -0.063 -0.062
ETl aero -0.059 -0.059 -0.059
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Table 2.9: Sensitivity coefficients for prospective calculation of effective dose from 
intakes of uranium isotopes via inhalation for a 10% change in each parameter
Model Parameter 234[; 235 J J 238 J J
Fractional nose deposition -2.012 -1.986 -T978
-0.546 -0.545 -0.544
AMAD -0.393 -0.393 -0.397
Breathing rate -0.433 -0.435 -0.440
Particle transport -0.310 -0.310 -0.310
ET2 aero -0.226 -0.223 -0.224
Sigma G -0.155 -0.153 -0.151
Blood to urinary bladder -0.074 -0.074 -0.076
f r -0.064 -0.063 -0.062
ETl aero -0.057 -0.057 -0.058
Table 2.10: Sensitivity coefficients for retrospective calculation of effective dose 
from intakes of uranium isotopes via inhalation for a 1% change in each parameter
Model Parameter 234^ 235 J J 238 J J
-1.156 -1.154 -1.153
AMAD 0.259 0.259 0.255
Particle transport -0.202 -0.200 -0.201
f r -0.192 -0.190 -0.190
Fractional nose deposition 0.154 0.178 0.187
Breathing rate 0.172 0.168 0.166
Sigma G -0.141 -0.140 -0.137
Urinary path to urinary bladder 0.129 0.129 0.127
Blood to STl -0.099 -0.100 -0.098
ET2 aero 0.086 0.090 0TK9
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2.5 Conclusion
The sensitivity analysis has identified the important parameters in the uranium 
systemic model for calculating the effective dose. The parameters that govern the 
removal of uranium through the bladder and the transfer of material into organs 
that store uranium for long periods of time following an intake, i.e. the skeleton 
and the liver, were highlighted as important parameters. The transfer parameter 
from blood to the long term retention in the massive soft tissue (ST2) also had 
a significant effect on the calculation of the effective dose coefficient. These 
parameters are important for the calculation of the effective dose coefficient as 
for adults the irradiation is integrated over a period of 50 years following the 
intake.
For bioassay purposes, the ST2 compartment is not significant and is a sink 
compartment for the percentage of activity seen outside of the named organs. 
However, for the calculation of the effective dose coefficient this activity is shared 
equally among the tissue mass of the rest of the body. Some of the organs that 
are included in this allocation of activity have an explicit weighting factor in the 
calculation of effective dose. The weighting of these organs in the calculation of 
effective dose, and the significant long term activity retention in this compart­
ment, means the calculated effective dose coefficient is sensitive to the transfer 
rate into this compartment.
For intakes by ingestion the most important parameter was seen to be the 
absorption rate from the alimentary tract into the blood, however the reliability 
of the dose coefficient for ingestion of uranium compounds is still dependent on 
the uncertainty in the systemic model parameters.
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For intakes by inhalation the calculated effective dose coefficient is far more 
sensitive to the lung solubility parameter, Sg, in the HRTM than to the systemic 
model parameters. This is due to the high radiation sensitivity of the lung, 
reflected in the organ weighting factor for the lung used in the calculation of 
the dose coefficient. Reliability of the dose coefficient for inhalation of uranium 
is therefore more dependent on the uncertainty in the HRTM parameters and 
the long term retention of uranium in lung tissue, than on those in the systemic 
model of uranium.
No significant difference was seen for any of the three isotopes used in the 
sensitivity analysis. The majority of the internal dose for each of the isotopes 
is due to alpha decay, so self-irradiation of organs/tissues dominates the dose 
calculation. As the target and source organs are the same, changes in the dose 
calculation are due to radionuclide deposition in the organs which is the same 
across the three isotopes.
In general, the results from the sensitivity analysis indicate that the uncer­
tainty on a number of systemic model parameters require consideration when 
performing a reliability analysis of the uranium effective dose coefficient for in­
takes of uranium by ingestion. For intakes by inhalation the HRTM parameters 
are likely to dominate the uncertainty, with the rate of removal of inhaled ac­
tivity from the lung being the dominant factor in calculating the effective dose 
coefficient.
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Estim ating Uranium Lung 
Solubility Param eters from  
Historical Bioassay D ata
^The sensitivity analysis in chapter 2  identified that for intakes via inhalation 
the HRTM parameters were the dominant biokinetic parameters for determining 
effective dose. In this chapter historical bioassay measurements from two nuclear 
establishments are analysed to provide estimates for the important uranium lung 
solubility parameters. A Bayesian method is used to account for the uncertainty 
in the bioassay measurements and the biokinetic parameters.
^Parts of this chapter have been submitted to the journal Radiation Protection Dosimetry
46
Chapter 3
3.1 Introduction
Effective doses resulting from inhalation are often calculated using the HRTM 
published by the ICRP [ICRP, 1994], coupled with a suitable systemic model that 
describes the uptake, retention and excretion of inhaled radionuclides following 
uptake to blood from the respiratory tract. Consideration of the uncertainties 
in these models and their parameter values is important to properly assess the 
statistical power of the epidemiological studies that are based upon them. In the 
same way these models are used to calculate effective doses for radiation protec­
tion purposes. Furthermore, because the same models are used to calculate the 
dose coefficients used in radiation protection, consideration of the uncertainties is 
required to assess the reliability of dose coefficients as a protection device [Puncher 
and Harrison, 2012b].
Intake via inhalation is the dominant pathway for occupational exposure to 
uranium materials [IAEA, 1999]. Internal dose estimates following inhalation can 
be estimated indirectly from measurements of uranium excreted in urine. In 
chapter 2  it was seen that the most important biokinetic model parameters that 
determine absorbed lung doses estimated from uranium in urine bioassay are those 
that describe the dissolution of the uranium particles in the lungs prior to uptake 
to blood - a process known as absorption[ICRP, 1994]. Accurate estimates of the 
values of these parameters are therefore prerequisite to obtaining best estimates 
of lung dose resulting from exposure to uranium.
In the HRTM the rate of absorption of inhaled particles from the respiratory 
tract to blood can be described by three parameters [ICRP, 1994]: a fraction 
of the material deposited in the lung, fy, dissolves rapidly at a rate sj, the
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remainder, ( 1  — fy), dissolves more slowly at a rate, Sg. Default parameter values 
are provided by the ICRP for inhaled materials that cover fast (Type F), medium 
(Type M) and slow (Type S) rates of absorption. Materials are assigned to one of 
these categories when the rate of absorption is not known but can be inferred, for 
instance, from the material’s physico-chemical characteristics. ICRP suggest that 
specific parameter values should be used where information is available [Valentin, 
2 0 0 2 ^
Specific absorption parameter values for uranium oxide compounds have been 
derived from in-vitro[Chazel et al., 1998][Chazel et al., 2001][Ansoborlo et al., 
1998][Ansoborlo et al., 2 0 0 2 ] and animal studies[Stradling][Chazel et al., 2 0 0 1 ][An­
soborlo et al., 1998][Ansoborlo et a l, 2 0 0 2 ][Pellow et a l, 2003] a recent review 
is provided by Davesne and Blanchardon[Davesne and Blanchardon, 2014]. The 
values of the absorption parameters for pure uranium oxide compounds deter­
mined in these studies cover a broad range:
f r  = 0.01 to 0.87 
Sr =  0.28 to 36d~^
Ss =  2.6 X 10“  ^ to 2.4 X
The use of material specific parameter values derived from in-vitro and animal 
studies is preferred over the generic solubility types provided by the ICRP [ICRP, 
1994]. However, there are three limitations with the use of such values for dose 
assessment:
1 . It is assumed that the values, determined from in vitro and animal studies, 
adequately describe the absorption behaviour of the materials in humans.
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2. The values are point estimates, provided without uncertainty, and so do 
not account for significant uncertainties in the model, parameter values 
and measurement data used to obtain them.
3. Finally, in an accident scenario the inhaled uranium particles may be in a 
variety of chemical states (a mixture) so that the overall solubility of the 
material is not well described by the lung absorption parameter values of a 
specific chemical form of uranium.
Under these conditions, the best approach is to estimate, if possible, the 
absorption parameter values from bioassay data collected from the exposed indi­
viduals.
Bayesian statistical methods provide an approach for deriving estimates of 
model parameter values directly from human bioassay measurement data and 
have been used in internal dosimetry to obtain best estimates on intakes, doses 
and biokinetic model parameter values[Avtandilashvili et a l, 2013][Miller et a l, 
2008][Puncher et a l, 2012][Puncher and Burt, 2013]. The method is attractive 
because it provides a best estimate of the parameter value of interest together 
with an uncertainty on the estimate (as a probability distribution); furthermore 
the method potentially reduces uncertainties on the estimate by incorporating 
existing knowledge regarding the parameters of interest into the Bayesian cal­
culation. This is particularly pertinent to internal dosimetry problems as the 
measurement data used to infer intakes and doses are often sparse and have sig­
nificant measurement uncertainties.
The aim of the work in this chapter is to obtain best estimates of the lung 
absorption parameters for uranium oxides from bioassay measurements obtained
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from nuclear workers who inhaled a significant amount of uranium. The study 
addresses the limitations noted above by applying Bayesian inference to esti­
mate absorption parameter values directly from the worker’s urine bioassay data. 
Specifically, the methodology is applied to historical bioassay data from six ura­
nium exposure cases: three workers exposed at facilities of the United Kingdom 
Atomic Energy Authority (UKAEA), and three from a nuclear establishment in 
the United States of America. The former is of particular relevance because ura­
nium exposures from UKAEA facilities were included in a recent epidemiological 
study, and will be included in future studies. The methodology is evaluated and 
discussed, and the results are compared with previously reported values for these 
materials.
3.2 Uranium Exposure Cases
The study considered the bioassay data collected following six different occu­
pational exposures to uranium: three (UK cases 1-3) occurring at facilities of 
the United Kingdom Atomic Energy Authority (UKAEA) and three (US cases 
K1-K3) occurring at the Oak Ridge Gaseous Diffusion plant, Tennessee, in the 
United States.
3.2.1 UK Case 1
Following the hot rolling of enriched uranium a split developed in the stainless 
steel casing leading to an individual having an acute intake of enriched uranium 
oxide via inhalation. Twelve 24 hour urine samples were taken after the intake 
with the first sample being taken on day 1  following the intake and the last follow
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up sample being taken 250 days after the intake. Eight faecal samples were also 
taken covering a period of day 1 to day 114 after the intake. The precise chemical 
form of the uranium oxide is unclear.
3.2.2 UK Cases 2 and 3
Two workers who were weighing and transferring enriched uranium in the form of 
surface oxidised metal from one can to another detected contamination on their 
gloves. Both individuals were thought to have had an acute intake of enriched 
uranium oxide via inhalation. For the first worker (case 2), six 24 hour urine 
samples were taken between days 2  and 32 after the initial intake. Seven faecal 
samples were taken between days 1 and 33 following the intake. For the second 
worker (case 3) six 24 hour urine samples were taken between days 2 and 32 
following the intake and six faecal samples were taken between days 2 and 31 
after the incident. The precise chemical form of the uranium oxide is unclear.
3.2.3 US Cases K l, K2 and K3
The bioassay data for three individuals exposed at the Oak Ridge Gaseous Diffu­
sion plant in Tennessee are those published by Schultz [Schult z, 1966]. The three 
individuals were placed on an extended bioassay study as they were thought to 
have had a significant acute inhalation of uranium material most likely a mixture 
of soluble UFq and (fyOg. Gase 1  provided 48 urine samples and 43 faecal samples 
over a period of 524 days following the initial exposure. Gase 2  provided 2 1  urine 
and 17 faecal samples over a period of 394 days. Case 3 provided 2 2  urine and 
18 faecal samples over a period of 382 days. Each of the individuals was a male
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chemical worker and the likely chemical form of the inhaled insoluble uranium 
oxide is C/gOg. No additional information on the particular circumstances of each 
exposure was provided.
3.3 Bioassay Measurement Uncertainty
Urine and faecal measurement uncertainties were assumed to be lognormally dis­
tributed. The likelihood function assumed for lognormal data is described else- 
where[Doerfel et al., 2006]. The geometric standard deviation assigned to urine 
and faecal measurements were assumed to be 1.8 and 3, respectively and are those 
derived empirically from similar data by Marsh et al.[Marsh et al., 2005][Marsh 
et al., 2008]
3.4 M ethod
Bayesian inference was applied to determine values of lung absorption parameters 
for uranium oxides (as probability distributions) from historical bioassay data. In 
Bayes theorem the probability of a particular set (vector) of model parameters, 
X, given a vector of measurement data, M, is given by:
p(X|M )ocp(M |X)p(X) (3.1)
Where:
p(X|M) is the posterior probability for the set of parameters X  given the mea­
surement data M
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p(M|X) is the probability of the measurement M  given the set of parameters X 
(also called the likelihood function)
p(X) is the prior probability distribution for the set of parameters X
For the analysis undertaken here the measurements, M, are the historical 
urine and faecal bioassay data and the set of parameters, X, are the biokinetic 
model parameters of interest (described below) and the intake parameter.
A significant issue in applying Bayes theorem is that the constant of pro­
portionality in equation 3.1 is typically a high dimensional integral that can be 
difficult, if not impossible, to solve analytically. Markov Chain Monte Carlo 
(MCMC) techniques are widely used in Bayesian analysis as they provide a nu­
merical method for estimating the posterior probability distribution without hav­
ing to determine the constant of proportionality[Gilks et ah, 1995]. In MGMG, 
model parameter values are sampled with a frequency that is proportional to the 
probability density of the posterior distribution of interest.
3.5 Biokinetic Models
A modified version of the ICRP HRTM was used that includes recent changes to 
the model of deposition and clearance of material deposited in the airways. These 
changes apply to the compartments representing particle transport clearance from 
the bronchial (BB), bronchiolar (bb), and alveolar-interstitial (AI) regions of the 
lung [Bailey et ah, 2007]; and deposition and clearance from the extra-thoracic 
(ET) region. ICRP is using the updated model to calculate revised dose coeffi­
cients for workers based on the ICRP Publication 103[IGRP, 2013] formalism for
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effective dose. The revised particle transport clearance model is given in figure 
3.1; descriptions of the proposed structural changes are provided elsewhere [Bailey 
et ah, 2007][Gregoratto et ah, 2010][Smith et ah, 2013]. Based on the results of 
recent nasal clearance studies, it is assumed that, of the material deposited in 
the ET region, 65% is deposited in ETl and 35% in the ET2 region [Smith et ah, 
2013]. The updated HRTM was assumed in the analysis here.
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Figure 3.1: Modified HRTM used in this analysis [Smith et ah, 2013]. The pul­
monary interstitial tissue (INT) is included in the modified HRTM. The com­
partments in the thoracic region have been reduced compared with the HRTM 
from IGRP publication 6 6 .
The modified HRTM was used in conjunction with the human alimentary 
tract model published by the ICRP in Publication 30[ICRP, 1979] and the IGRP
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Publication 69 systemic model for uranium [ICRP, 1995a].
3.5.1 Selection of Prior Probability Distributions
Prior probability distributions for intake and the key lung parameters affecting 
deposition and clearance from the lungs were defined. For the three dissolution 
parameters (/r, Sr and Sg), uniform (uninformative) prior distributions were as­
sumed in order that the calculated marginal posterior distributions of parameter 
values would refiect only information provided by the bioassay data. The prior 
distributions for the absorption parameters are shown in table 3.1.
Table 3.1: Uniform prior probability distributions for the three lung solubility
parameters in the HRTM________________________________________
Model Parameter Prior Probability Distribution
Slow absorption rate, Sg {d~^) U(0, 0.1)
Rapidly absorbed fraction, fr U(0, 1)
Rapid absorption rate, Sr (d~^) U(0.1, 100)
The prior distributions for other parameters are summarised in table 3.2. The 
lognormal distributions for the particle activity median aerodynamic diameter 
(AMAD) and the aerosol particle geometric standard deviation (ag) are based 
upon a review of published workplace aerosol size distributions by Dorrian and 
Bailey[Dorrian and Bailey, 1996].
The uncertainty on the particle transport rates from the upper airways (from 
compartment bbl onwards) were assumed to be correlated, so that each parameter 
was varied by the same random variable, Kpt, sampled from a lognormal distri­
bution with median value of unity and GSD of 1.73. This distribution represents 
primarily inter-subject variability in the rate of particle transport clearance from 
the upper airways in human subjects[lCRP, 1994].
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The prior probability distributions for the particle transport parameters from 
the alveolar-interstitial region are those derived by Gregoratto et al [Gregoratto 
et a l, 2 0 1 0 ]. A uniform prior distribution was assumed for the intake in each 
case, with a minimum value of zero and maximum value of 1  x 10® Bq.
Table 3.2: Prior probability distributions for other important parameters in the
HRTM________________ ____________________________________________
Model Parameter Prior Distribution
Particle transport rate factor, Kpt LN(1, 1.73)
Activity median aerodynamic diameter, AMAD (fim) LN(4.4, 1.8)
Aerosol geometric standard deviation, ag LN(2.2, 1.5)
Alveolar to bronchiolar region, Alv to bbl (d~^) LN(1.3 x 1 0 “^^  3.2)
Alveolar to interstitial region, Alv to Int (d~^) LN(1.0 x lO'^, 4.5)
Interstitial to lymphatic nodes, Int to Lnth (d~^) LN(3.0 x 10“ ,^ 3)
3.6 Computational M ethod
The MGMG algorithm used here is described in detail by Puncher and Bir­
chall [Puncher and Birchall, 2008]. The method is a standard implementation 
of the single component Metropolis algorithm [Metropolis et a l, 1953]. The al­
gorithm is implemented in a computer code that uses the dosimetry code IMBA 
Professional Plus [Birchall et a l, 2007], to calculate bioassay predictions using the 
HRTM and IGRP publication 69 systemic model for uranium[ICRP, 1995a]. For 
each analysis the following was performed:
1. The prior distributions for the lung parameters and intake were set in the 
MGMG code.
2. Normal distributions were assumed as proposal distributions for all param­
eters. Initially, the standard deviation of the proposal distribution was set
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at 1 0 % of the mean value of the proposal distribution, but subsequently 
adjusted if required in step 3.
3. The acceptance frequency of sampled parameters was monitored. If the 
acceptance frequency was deemed too high (>70%) or to low (<20%) then 
the standard deviation of the proposal distribution were adjusted and the 
chain re-initiated. This step was repeated until the acceptance frequency 
remained within the stated bounds.
4. The parameter values from each realisation of the Markov Chain were 
recorded.
For each analysis, two chains were run. The chains were considered to have 
adequately converged to the posterior distribution when the mean values from 
the two chains were within 5%, after discarding the first 1000 iterations to allow 
for burn-in of the chains. The chains are said to burn in as a number of the initial 
samples may be taken in areas of low probability in the target distribution. Once 
the chain has converged onto the target distribution the remaining samples were 
used to estimate the mean, median and other parameters of interest from the 
posterior distribution of model parameters and intake in the usual way [Puncher 
and Birchall, 2008].
3.6.1 Obtaining Bayesian estim ates of absorption param­
eters
MCMC was applied to obtain estimates of the absorption parameter values from 
the cases in two ways:
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1 . Individual estimates. Posterior distributions of lung parameters and intake 
were obtained from an analysis of the data for each worker in isolation. 
In other words, MCMC was applied to calculate the posterior given in 
equation 3.1, where M is the vector of worker data and X the vector of 
HRTM parameters and intake.
2 . Shared estimates. The data for selected cases were analysed together to 
obtain shared estimates of the absorption parameters. Under these cir­
cumstances, the values of the material specific absorption parameters and 
aerosol AMAD and CSD, are assumed to have, once selected, the same 
(shared) value for each worker, but the other, individual specific, HRTM 
parameters and intake are assumed to have different values for each worker 
(are unshared). More precisely, MCMC is applied to calculate the following 
posterior distribution:
p(S.X|M ) (3.2)
Where:
S is a vector consisting of the parameters that are shared 
X is a matrix of the remaining individual specific HRTM parameters and intakes 
M is a matrix of worker bioassay data
The cases analysed using the second approach (2) were grouped by exposure 
as follows:
1 . UK Cases 2 and 3
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2 . US Cases K1-K3
3.7 Results
3.7.1 Lung Dissolution Param eters
Tables 3.3 - 3.10 summarise the statistics from the posterior marginal distribu­
tions generated for the dissolution parameters in each Bayesian analysis. It is 
worth noting that the prior probability distributions assumed for each of the sol­
ubility parameters was a broad uniform distribution; therefore, if the bioassay 
data is uninformative for these parameters then the calculated posterior proba­
bility distribution will also be broad and uninformative. The main results are 
summarised below.
3.7.1.1 U K A E A  cases 
Analysis of individual cases:
• The data are uninformative for the rapid dissolution rate, Sr, with the 95% 
range covering most of the prior range (0 .1 - 1 0 0 ).
• The GSD values are high for the rapid fraction, fy; however this is because 
the data appears to support a range starting from low initial values, to 
relatively higher 97.5% values of 0.08 (case 1); 0.36 (case 2) and 0.37 (case 
3). The median values are 0.013 (case 1); 0.064 (case 2) and 0.07 (case 3). 
The results suggest the oxide form for case 1 has lower lung solubility than 
cases 2 and 3.
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• The data appear to be more informative for the slow dissolution rate, Sg, 
although the 95% range is around an order of magnitude or more. The rate 
appears to be lower for case 1, compared with cases 2 and 3: a median value 
of 0.0035 (case 1) versus 0.0075 (case 2) and 0.0095 (case 3).
• The values of fr and Sr suggest a lower solubility form of uranium oxide for 
case 1, compared with cases 2 and 3. The distributions for case 2 and 3 are 
very similar.
Shared analysis:
• Combining the data for cases 2 and 3 significantly affects the estimates 
of the rapid fraction and slow dissolution rate, but provides no additional 
information regarding the rapid dissolution rate, Although the geometric 
range of fr is essentially the same as observed in the individual analyses, 
as indicated by a GSD of 3.6, the shared analysis suggests a lower value of 
around 0.04, with an upper 97.5% value of 0.23.
• Combining the data improves the estimate of the slow dissolution rate, and 
like fr, appears to support a lower value as indicated by a median of 0.006 
and 95% range of around 0.002 to 0.02.
3.7.1 . 2  US cases 
Analysis of individual cases:
• As for the UK cases, the US data provides little additional information 
regarding the rapid dissolution rate that is not already provided by the 
prior distribution. The 95% range of the rapid fraction is also similar to
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the UK data, but indicates a much lower value of around 0.004-0.005 (a 
factor of 20 lower than UK case 1), with an upper 97.5% value of 0.03-0.04, 
as indicated by the posterior median and 97.5% values, respectively.
• The individual analysis of the US cases produced marginal posterior distri­
butions with median values for of 1.6 x 10“ ,^ (Kl), 3.5 x 10“  ^ (K2) and 
3.0 X 10“  ^ (K3). These appear to be similar to UK case 1, and therefore less 
soluble than UK cases 2 & 3. However the US data appears to be more in­
formative for this parameter, probably because the data were collected out 
to much later times than the UK data: the GSDs of the marginal posterior 
distributions have GSDs that ranged from 1.2-1.3, compared with around 
2 for the UK data.
• The posterior distributions of the dissolution parameters are very similar 
for the three cases.
Shared analysis:
• As for the UK cases, combining the data for all three cases significantly 
affects the estimates of the rapid fraction, /r, but provides no additional 
information regarding the rapid rate. Again, the shared analysis suggests 
a lower value of fr compared with the individual analyses: for the US data 
the median value is around 0 .0 0 2 , which is around a factor of two or more 
lower than the individual estimates; the 97.5% value is around a factor of 3 
lower than the same values from the individual analyses; the shared 2.5% 
value is shifted downwards with the result that the GSD is maintained at 
around a value of 4.
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• Combining the data does not appear to affect the geometric range for Sg, 
but as observed for fr, appears to support a lower value as indicated by a 
median of 0.002 and 95% range of around 0.0014 to 0.0026.
3.7.2 Other Parameters
The posterior distributions of the other HRTM parameters: aerosol AMAD and 
GSD, and particle transport clearance rates, particularly the rate from interstitial 
tissue to the thoracic lymph node, were very similar to their prior distributions, 
suggesting that (as expected) the urine bioassay data provide little additional in­
formation regarding these parameters. The parameter that describes the transfer 
of material from the interstitial fluid to the thoracic lymph nodes does not affect 
activity excreted in urine at all. However, this parameter acts as a useful positive 
control for the MGMG analysis as the marginal posterior distribution should be 
identical to the prior probability distribution, and this is what was observed in 
this analysis. The logarithm of the samples drawn from the posterior distribution 
for UK case 1 were plotted in a histogram to illustrate this effect (figure 3.2) it is 
clearly a lognormal distribution with median value of 0.00003 and GSD of 3. For 
comparison, the posterior and prior distributions of the slow dissolution rate, Sg, 
for the same UK case are plotted in figure 3.3. This shows that the urine data 
are clearly informative for this parameter.
3.8 Discussion
In this study, a Bayesian analysis was performed on six historic uranium oxide 
exposure cases to derive best estimates, as probability distributions, of the lung
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Table 3.3: UKAEA Case 1 Posterior Results
f r Sj- S s
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
2.00 X 10-2 
1.25 X 10-2 
3.90
8 . 0 2  X 1 0 - 2
3.73 X 10-4
4.13 X 101 
3.70 X 101 
3.31
9.63 X lOi 
1.06
3.79 X 10-2 
3.47 X 10-2
1.73
8.26 X  10-2
9.74 X 10-4
Table 3.4: UKAEA Case 2 Posterior Results
f r S f Ss
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
9.43 X 10-2 
6.36 X 10-2 
3.77
3.58 X 10-1 
2.15 X 10-2
4.04 X 101 
3.53 X lOi 
2 . 8 6
9.61 X  lOi 
2.30
9.80 X 10-2 
7.50 X 10-2 
2.38
3.11 X 10-2 
1.16 X 10-2
Table 3.5: UKAEA Case 3 Posterior Results
f r Sr Ss
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
1.01 X 10-1 
6.97 X 10-2 
3.49
3.66 X 10-1 
2.79 X 10-2
4.17 X 101 
3.72 X lOi 
2.97
9.64 X 101 
2.05
1.16 X 10-2 
9.46 X 10-2 
2 . 1 2
3.32 X 10-2 
1.85 X 10-2
Table 3.6: UKAEA Cases 2  and 3 Shared Posterior Results
f r Sr S s
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
5.88 X 10-2 
3.92 X  10-2 
3.62
2.28 X 10-1 
1.53 X 10-2
3.93 X 101 
3.32 X IQi 
2.96
9.59 X 101 
2.19
6.92 X  10-2 
5.77 X 10-2 
1.89
1.87 X 10-2 
1.56 X 10-2
Table 3.7: US Case Kl Posterior Results
f r S r S s
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
7.64 X  10-2 
5.17 X 10-2
3.65
2.92 X 10-2 
1.80 X 10-4
4 .4 4  X 101 
4.19 X 101 
3.18
9.68 X 101 
1.27
1.57 X  10-2 
1.56 X 10-2 
1.24
2.23 X 10-2 
9.66 X 10-4
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Table 3.8: US Case K2 Posterior Results
f r S f Ss
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
6.78 X 10-2 
3.84 X 10-2 
4.02
3.28 X 10-2 
1.33 X 10-4
4.27 X 10' 
3.97 X 104 
4.04
9.68 X  104 
4.08 X 10-4
3.56 X 10-2 
3.54 X  10-2 
1.27
5.21 X 10-2 
2.05 X 10-2
Table 3.9: US Case K3 Posterior Results
f r S f Ss
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
7.94 X  10-2 
4.24 X  10-2 
4.15
3.86 X 10-2 
1.34 X 10-4
4.22 X 104 
3.90 X 104 
4.26
9.66 X 104 
3.12 X 10-4
3.04 X 10-2 
3.01 X 10-2 
1.32
4.70 X 10-2 
1.60 X  10-2
Table 3.10: US Shared Case Posterior Results
f r Sr Ss
Mean
Median
Geometric Standard Deviation 
97.5th Percentile 
2.5th Percentile
2.80 X 10-2 
1.66 X 10-2 
3.89
1.33 X 10-2 
5.38 X 10-5
4.48 X 104 
4.34 X 104 
4.51
9.71 X 104
2.49 X 10-4
2.02 X  10-2 
2.01 X 10-2 
1.17
2.64 X 10-2 
1.43 X 10-2
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Figure 3.2: Histogram of the rate from interstitium (Int) to thoracic lymph node 
(Lnth)
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Slow dissolution parameter, Ss (day^)
Figure 3.3: Histogram of the slow dissolution rate
dissolution parameters for uranium oxides. The bioassay data in all of the ex­
posure cases considered here provided useful information for estimating values of 
the rapid fraction, fr, and the slow dissolution rate, Sg.
The US data is particularly informative for Ss as the urine bioassay was col­
lected for a period of up to two years after exposure and the measured urine 
activity over that period is closely correlated with the slow dissolution rate of 
uranium material deposited in the lungs.
Accurate estimates of the value of the slow dissolution rate are particularly 
important because this parameter strongly influences lung doses estimated from 
urine bioassay following inhalation exposure. The values for Ss determined here 
are broadly similar to the corresponding Type M parameter value for uranium 
materials provided by the ICRP (sg =  5 x 10“^)[ICRP, 1994].
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For the UK cases, the physico-chemical form of the uranium oxide is unknown, 
but the values of the slow dissolution rate are around an order of magnitude 
higher than values for uranium dioxide derived in a recent study by Davesne and 
Blanchardon[Davesne and Blanchardon, 2014], and earlier values determined by 
Hodgson et al [Hodgson et al., 2000].
Instead, the values appear to be more consistent with those for UO3 , C/O4  
or even UgOg [Davesne and Blanchardon, 2014]. The values of the slow dissolu­
tion rate for UgOg determined from the US data are in very good agreement with 
those derived by Davesne and Blanchardon [Davesne and Blanchardon, 2014] from 
animal data, consistent with a value of around 0.002 d~^. However, the 97.5% 
value of the rapid fraction is lower than that reported by Davesne and Blan­
chardon [Davesne and Blanchardon, 2014]. This could be a consequence of the 
wide prior distribution of Sr, or more likely, the fact that other physico-chemical 
factors, such as hydration state or aerosol size, affect differences in the dissolution 
characteristics of UgOg materials [Davesne and Blanchardon, 2014].
The calculated posterior distributions for the rapid dissolution rate Sr, were 
broad in all cases, indicating that little additional information was provided by the 
urine bioassay data for this parameter. The rapid rate does not have a significant 
effect on the uranium activity observed in urine bioassay data collected more than 
a few days after an intake has occurred.
For the individual analyses of the US cases the posterior estimates of fr and 
Ss are broadly similar between individuals; this is also observed for UK cases 
2 & 3. This observation supports the assumption that the rate of dissolution 
is a physico-chemical, rather than physiologically dependent, process and so is 
expected to occur at the same rate in the lungs of all individuals exposed to
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the same material. Thus, sharing or pooling the data, in the manner described, 
provides an opportunity to better estimate values for these parameters.
The sharing of data between two of the UK cases lead to a more noticeable 
improvement in the estimate of the parameter values compared with the US 
data. The bioassay regime for the latter was designed specifically to be used 
for estimating lung solubility, and as noted, is particularly useful for estimating 
values of the slow dissolution rate. In contrast, the UK cases represent what can 
be considered typical industrial accident scenarios where the spéciation of the 
uranium oxide is not particularly well characterised and the bioassay follow up 
is limited. As each of the UK cases had only a limited amount of bioassay data 
following the suspected intake, pooling the bioassay data has greater potential to 
yield better estimates of the dissolution parameters than is expected when the 
cases are analysed individually.
The UKAEA data highlight two important points regarding the use of urine 
bioassay data to reconstruct lung doses resulting from occupational inhalation 
of uranium bearing aerosols for epidemiology studies (and other actinide bearing 
aerosols for that matter). Firstly, these data, which are probably above average 
in terms of data quality for occupational exposures, support a broad range of dis­
solution parameter values, and hence lung doses. This re-enforces the fact that 
uncertainties on these parameter values should be reduced as much as possible 
to ensure the accuracy of risk estimates derived from them. Secondly, when the 
chemical identity of the inhaled material is unclear (as it is for these exposures), 
then estimating dissolution parameter values directly from members of the co­
hort helps to avoid introducing potential bias that may occur if the values are 
instead inferred from the (assumed) chemical form. In other words, for the pur-
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pose of ensuring accurate dose reconstruction, if the dissolution parameter values 
are known then it does not matter whether the chemical form can be precisely 
identified or not.
Using the shared approach described here, an improved estimate of the lung 
dissolution parameters may be obtained for a particular facility using a suitable 
number of exposure cases. Such an approach has been used by Puncher et al 
(in preparation) to estimate the slow dissolution rate for plutonium nitrate and 
oxide materials from autopsy data of former workers of the Mayak Production 
Association.
The results indicate that the urine bioassay data are broadly uninformative 
for the other HRTM parameters. As noted, this is because these parameters have 
a small effect on the predicted amount of uranium excreted in urine, and therefore 
are likely to have little effect on posterior estimates of the dissolution parameters.
3.9 Conclusion
Bayesian inference provides a useful framework to estimate values of dissolution 
parameters, and the associated uncertainty on these estimates, from human urine 
bioassay data. The sharing of information between groups of workers who are ex­
posed to the same chemical form of uranium was shown to reduce the uncertainty 
on the key lung solubility parameters. In chapter 4 the uncertainty on the lung 
solubility parameters seen here will be used to estimate the total uncertainty on 
the effective dose from uranium intakes via inhalation.
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Uncertainty in ICRP Dose 
Coefficients for Uranium
4.1 Introduction
As discussed previously the ICRP dose coefficients are used to convert an intake 
of radioactivity into an effective dose. The ICRP calculate dose coefficients for 
a wide variety of radionuclides and different intake pathways [ICRP, 1995b]. The 
effective doses calculated using the ICRP dose coefficients are used in practical 
radiation protection to provide an indication of the risk associated with a partic­
ular intake. In addition they are used to compare internal doses to annual dose 
limits for regulatory purposes. While the dose coefficients are considered nominal 
risk coefficients without an associated uncertainty an understanding of the uncer­
tainties in deriving the coefficients is useful for assessing their reliability [Puncher 
and Harrison, 2012b].
The uncertainties in each of the biokinetic model parameters contributes to an
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overall uncertainty in the calculated dose coefficient. The size of the uncertainty 
on the dose coefficient provides an indication of how reliable it is for regulatory 
and radiation protection purposes.
In this chapter an uncertainty analysis of the effective dose coefficient from 
occupational exposures to uranium compounds is presented. The posterior distri­
butions for the important lung solubility parameters that were derived in chapter 
3 will be used to inform the probability distributions for those parameters here. 
The probability distributions for the key biokinetic model parameters are shown 
in table 4.1. The biokinetic parameter distributions are randomly sampled to 
generate a vector of biokinetic parameter values. The effective dose coefficient 
is calculated using each of the vectors of sampled biokinetic parameters. This 
produces a distribution of calculated effective dose coefficients.
Computational uncertainty analysis of this type has proved to be a useful 
method for deriving probability distributions for specific dose coefficients [Apos- 
toaei and Miller, 2004] [Puncher and Birchall, 2008]. The uncertainty analysis 
undertaken here complements the analysis for environmental exposures to ura­
nium reported by Puncher and Burt [Puncher and Burt, 2013]. In that paper 
uncertainty factors for the public uranium dose coefficients were derived from 
the best estimates for the probability distributions for the biokinetic parameters 
for member of the public across a wide variety of age ranges. Here we will use 
probability distributions for adult workers to estimate an uncertainty factor for 
occupational dose coefficients for uranium exposures.
In addition to the uncertainty analysis for the uranium dose coefficients for oc­
cupational exposures, the uncertainty in assessing a dose from a bioassay measure­
ment is also estimated here. The retrospective dose uncertainty was calculated
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assuming an inhalation exposure had occurred in the middle of the monitoring 
period.
4.2 M ethod
A Latin-Hypercube sampling technique [McKay et al., 1979] was used to sample 
values from the probability distributions for the biokinetic parameters shown in 
table 4.1.
Latin-Hypercube sampling was used as it is shown to reduce the number of 
samples required to achieve convergence in this type of analysis [Khursheed and 
Fell, 1997]. To generate the Latin-Hypercube the number of samples required 
from each parameter, N, is set. The probability distributions for the parameters 
to be sampled are then split into 1 /N  non-overlapping areas of equal probability. 
A random sample is drawn from each to provide N samples for each particular 
parameter. If the number of parameters to be sampled is n, the samples are then 
randomly coupled to form a matrix of N x n sampled parameters that should 
provide an adequate representation of the total parameter space for all of the 
parameters.
1 0 0 0  samples were taken from the parameter distributions for each biokinetic 
parameter to form the vector of parameters for calculating the dose coefficient. 
Each vector of sampled biokinetic values was then used to calculate an effective 
dose for a unitary intake i.e. the dose coefficient for that selection of parameters. 
This technique produced a probability distribution for the dose coefficient.
The Monte Carlo software tool used in this chapter was developed by Puncher 
and Birchall [Puncher and Birchall, 2008]. The software uses the dosimetry code
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IMBA[Birchall et al., 2007] to solve the biokinetic models to calculate bioassay 
predictions and doses.
This analysis generated probability distributions for effective dose coefficients 
from which uncertainty factors were calculated to provide an indication of the 
uncertainties in the dose coefficients. The method was then extended to include 
going from a bioassay measurement to an effective dose to see how the distribution 
of effective dose is altered due to the biokinetic model being applied twice.
4.2.1 Biokinetic Param eter Probability D istributions
The biokinetic parameter probability distributions used in this study are shown 
in table 4.1.
4.2.1.1 Lung Solubility Param eters
The probability distributions for the lung solubility parameters used in this un­
certainty analysis was based on the results of the analysis in chapter 3. The 
bioassay data used to derive estimates for the lung solubility parameters was 
from occupational intakes of uranium. The results of the analysis in chapter 3 is 
therefore applicable to the uncertainty analysis here. The derivation of the three 
lung solubility parameters is discussed below:
f r  The analysis of the bioassay data in chapter 3 was fairly uninformative for 
the fast solubility parameter /^. The uncertainty in this parameter for 
occupational uranium exposures is large and therefore a broad probability 
distribution is required. The results presented in chapter 3 suggest a broad 
lognormal distribution with a median that represents the ICRP default
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Type M material value (1 x 10“ )^ and a geometric standard deviation of 3 
is representative of the uncertainty in this parameter.
Sr The results in chapter 3 were not informative for the rapid absorption frac­
tion Sr. Puncher and Burt [Puncher and Burt, 2013] suggested a lognormal 
distribution with median 1 and GSD 4 based on evidence from a number 
of studies. This broad distribution will be used in this assessment of the 
uncertainty in uranium dose assessments.
Ss The posterior distributions for this parameter seen in chapter 3 suggest a 
lognormal distribution with a median value of 2  x 1 0 “  ^and a GSD of 3 covers 
the range of values seen in these posterior distributions. This is narrower 
than the distribution used in Puncher and Burt [Puncher and Burt, 2013] 
but that is reasonable as there is likely to be more certainty on the chemical 
form for occupational exposures than for environmental exposures.
4.2.1.2 Other Lung Param eters
In addition to the solubility parameters there are a number of important physical 
lung parameters that have been included in this analysis.
AMAD Typical values for AMAD for occupational aerosols were reviewed by 
Dorrian and Bailey[Dorrian and Bailey, 1996] and a lognormal distribution 
with a median of 4.4/zm and a GSD of 1.8 was seen to be representative of 
the experimental values seen.
Sigma G The dispersion of the aerosol distributions was seen to be described 
by a lognormal distribution with a median of 2.2 and a GSD of 1.5[Dorrian 
and Bailey, 1996].
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Br The breathing rate variation among adult males was estimated to be rep­
resented by a lognormal distribution of median 1.2 m^.hr~^ and a GSD of 
1.2 .
Fn Puncher et al[?] proposed that a right angled triangular distribution with a 
minimum of 0.4 and a vertex and maximum of 1 was representative of the 
variation in the fraction of air breathed through the nose.
Kpt For the upper airways the physical particle transport is assumed to be 
correlated as the mechanism is similar. Physical transport parameters are 
thought to vary by a factor of 3 and therefore a lognormal distribution with 
a GSD of 1.73 is representative of the uncertainty on these parameters. 
As discussed by Puncher et al the parameters are correlated and therefore 
a lognormal distribution with a median of 1  and a GSD of 1.73 will be 
sampled and multiplied by the upper airways particle transport parameters 
to provide the sample from the probability distribution for each parameter.
Alv to bbl, Alv to INT and INT to Lnth The probability distributions on the 
particle transport in the deep lung are based on the analysis by Gregoratto 
et al [Gregoratto et al., 2010]. Each parameter is given an individual prob­
ability distribution as it is thought the physical processes governing each 
parameter are different.
4.2.1.3 Absorption in the Alim entary Tract
Absorption of uranium in the alimentary tract is known to vary considerably in 
the population [Leggett and Harrison, 1995] [Harrison et al., 2001]. An analysis of 
the results for absorption of uranium by members of the public in Ganada[Zamora
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et al., 2 0 0 2 ] by Alexandrou[Alexandrou, 2010] suggested a lognormal distribution 
for the FI value with a median of 0.01 and a GSD of 2.4. This distribution for 
the fl parameter is used in this analysis.
4.2.1.4 T im e o f Intake
For the retrospective analysis the probability distribution on time of intake is 
modelled as being be flat over the 90 day period between urine bioassay sampling.
4.2.1.5 Uranium  System ic Param eters U ncertainty
The uncertainty on the systemic parameters is not well characterised. The sensi­
tivity analysis that was reported in chapter 2  provides guidance on which systemic 
model parameters are important for calculating the effective dose. The important 
systemic model parameters that produced the greatest effect on the effective dose 
calculated were:
• Uptake and retention in the skeleton
• Uptake and retention in the liver
• Uptake and retention in massive soft tissue
• Transfer from blood to urinary bladder contents
The uncertainty on each of these parameters is not well characterised due 
to the paucity of in-vivo data for healthy adults. A number of volunteer stud­
ies [Struxness et al., 1956][Bassett et al., 1948][Terepka et al., 1964] featuring se­
riously ill patients who were injected with uranium were carried out and these 
results formed the basis of the uranium biokinetic models. The approach adopted
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by Puncher and Burt [Puncher and Burt, 2013] was to tune the probability distri­
bution for each systemic parameter so that it reproduced the range of data seen 
in these human in-vivo studies^. They can be viewed as broad best estimates of 
the uncertainty. Further discussion on each parameter can be found in Puncher 
and Burt [Puncher and Burt, 2013].
Table 4.1: Probability Distributions for Biokinetic Parameters
Biokinetic Parameter Median GSD
f r 0 . 0 1 4
Sr 1 4
0.005 3
AMAD 4.4 1 . 8
2 . 2 1.5
Br 1 . 2 1.3
Fn Triangular 0.4, 1,1
Kpt 1 1.73
fl 0 . 0 1 2.4
Time of intake U(0,90)
Alv to bbl 0.0013 3.2
Alv to Int 0 . 0 0 1 4.5
Int to Lnth 0.00003 3
Blood to CS/TS 1 1.3
CS/TS to Other 1 3
Exchange CV/TV to Other 1.4
NExch CV/TV to Other 1 1.4
Blood to ST2 1 1.7
Blood to Liver 1 1 1.4
Blood to Bladder contents 1 1.73
^For the systemic parameters the default values are multiplied by the sample taken from 
this distribution that has a median value of 1
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4.2.2 Prospective M onte Carlo Calculations
The following steps were performed assuming an acute intake of IBq of 
and by both ingestion and inhalation:
1. Each biokinetic parameter was sampled from its assigned probability dis­
tribution using a Latin-Hypercube sampling algorithm.
2 . A vector of biokinetic parameters was established for the set of sampled 
parameters.
3. The parameter values were written to IMBA Professional Plus dosimetry 
code.
4. The effective dose was calculated for the vector of biokinetic parameters.
The above steps were performed 1000 times for each combination of uranium 
isotope and intake method. This produced 1000 values for the effective dose for 
a 1 Bq intake.
4.2.3 R etrospective M onte Carlo Calculations
To estimate an uncertainty in the calculation of effective dose from a bioassay 
measurement it is assumed that an acute intake of uranium occurred 45 days 
before the urine bioassay measurement was taken. This is to simulate a 3 month 
bioassay monitoring period. The bioassay measurement was a 1 mBq uranium 
activity in urine measurement. This measurement of uranium in urine would not 
be large enough to instigate additional monitoring on most nuclear sites in the 
UK however the size of the urine measurement does not impact the uncertainty
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analysis carried out here. The Monte Carlo calculation was then performed in 
a similar manner as for the prospective dose calculation to estimate the intake 
from the bioassay measurement.
1. Each biokinetic parameter was sampled from its assigned probability dis­
tribution using a Latin-Hypercube sampling algorithm.
2 . A vector of biokinetic parameters was established for the set of sampled 
parameters.
3. The parameter values were written to IMBA Professional Plus dosimetry 
code.
4. The intake was was calculated for the vector of biokinetic parameters.
The first Monte Carlo calculation produces a distribution for the intakes from 
the bioassay measurement. This distribution was then used as the probability 
distribution for the intake parameter. The Monte Carlo calculation was repeated 
using the same probability distributions for the biokinetic parameters shown in 
table 4.1 with the calculated intake probability distribution also being sampled.
4.3 Results
The results reported by Puncher and Burt [Puncher and Burt, 2013] showed that 
the uncertainty in effective doses to members of the public from intakes of uranium 
was approximately a factor of 2 for inhalation and 3 for ingestion. In this study 
the doses to workers were calculated for both the prospective and retrospective 
calculation of doses. The uncertainty factor here is calculated by considering the
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spread in the distribution obtained in the effective dose for both prospective and 
retrospective calculations. The uncertainty factor for each distribution of effective 
dose is estimated by taking the ratio of the 97.5th percentile to the mean of the 
distribution and the ratio of the mean of the distribution to the 2.5th percentile. 
The larger value is taken as the uncertainty factor for that distribution.
UF = Qgj^^/Mean (4.1)
or
UF = Mean/Q2.B (4.2)
The retrospective calculation of doses is required for workers as they are likely 
to provide bioassay measurements that can be used to calculate the effective dose.
4.3.1 Prospective Dose Uncertainty
Figures 4.7 - 4.11 and tables 4.2 - 4.4 show the distribution of effective doses 
calculated for ingestion of uranium compounds using the Monte Carlo technique. 
As can be seen the uncertainty factors calculated for the three isotopes were 
6.5, 5.6 and 6.4. These uncertainty factors were similar as would be expected as 
the biokinetic models are the same for the three different isotopes. The results 
obtained were larger than those reported by Puncher and Burt [Puncher and 
Burt, 2013] for uranium ingestion intakes.
Figures 4.4 - 4.6 and tables 4.5 - 4.7 show the distribution of effective doses 
calculated for inhalation of uranium compounds using the Monte Carlo technique. 
As can be seen the uncertainty factors calculated for the three isotopes were 4.0,
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Table 4.2: Uncertainty on prospective dose calculation for ingestion of (Sv)
Mean 4.55 X 10-*
Standard Deviation 5.78 X 10-*
Median 2.82 X 10-*
Geometric Standard Deviation 2.37
Q97.5 97.5th Percentile 1.95 X 10-^
Q2.5 2.5th Percentile 6.96 X 10-^
Q9 7 .5 /Meari 4.3
Mean/Q2.5 6.5
4.37E+02
o 2.19E+02 H
O.OOE+00
Total Effective D ose
4J61E-09 6.58E-07
Effective Dose (Sv)
Figure 4.1: Distribution of calculated prospective doses for ingestion of 
(distributions are screen grabs from the uncertainty analyser software developed 
by Puncher and Birchall [Puncher and Birchall, 2008])
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Table 4.3: Uncertainty on prospective dose calculation for ingestion of (Sv)
Mean 4.12 X  10-*
Standard Deviation 4.52 X  10-*
Median 2.69 X 10-*
Geometric Standard Deviation 2.25
Q9 7 .5 9 7 .5 th Percentile 1.65 X 10-^
Q2 .5 2 .5 th  Percentile 7.34 X  10-^
Qg7.5/Mean 4.0
Meanj  Q2.5 5.6
4.79E*02
o 2,40E*02-
Total E ffective D o s e
SaSG4B
Effecthm Dose (^v)
5.19E-07
Figure 4.2: Distribution of calculated propsective doses for ingestion of
Table 4.4: Uncertainty on prospective dose calculation for ingestion of (Sv)
Mean 4.09 X 10-*
Standard Deviation 4.95 X  10-*
Median 2.51 X 10-*
Geometric Standard Deviation 2.37
Q9 7 .5 9 7 .5 th Percentile 1.60 X  10-^
Q2 .5 2 .5 th Percentile 6.39 X 10-9
Qg7.5/Mean 3.9
Mean/Q2.5 6.4
82
Chapter 4
T otal E ffective  D o s e
SÆ5E+02
w 2.78E+02-
u_
Effective D ose (Sv)
S22E-07
Figure 4.3: Distribution of calculated propsective doses for ingestion of *^*(7
3.9 and 3.9. As seen by Puncher and Burt [Puncher and Burt, 2013] for public 
exposures the uncertainty factor obtained for inhalation exposures was lower than 
that seen for ingestion.
Table 4.5: Uncertainty on prospective dose calculation for inhalation of (Sv)
Mean 7.55 X 10-*
Standard Deviation 5.13 X 10-*
Median 6.16 X  10-*
Geometric Standard Deviation 1.85
Q9 7 .5 9 7 .5 th Percentile 2.14 X 10-*
Q2 .5 2 .5 th Percentile 1.90 X  10-*
Qgj.s/Mean 2.8
Mean/Q2 .5 4.0
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T otal E ffective D o s e
1XI9E+03-Î
4.44E-07 5D7E41S
Effective Dose (Sv)
Figure 4.4: Distribution of calculated propsective doses for inhalation of
Table 4.6: Uncertainty on prospective dose calculation for inhalation of *^*(7 (Sv)
Mean 6.75 X 10-*
Standard Deviation 4.63 X 10-*
Median 5.43 X 10-*
Geometric Standard Deviation 1.84
Q9 7 .5 9 7 .5 th Percentile 1.86 X 10-*
Q2 .5 2 .5 th Percentile 1.72 X  10-*
Qgy.s/Mean 2.8
Mean/Q2.B 3.9
Table 4.7: Uncertainty on prospective dose calculation for inhalation of *^*(7 (Sv)
Mean 6.28 X 10-*
Standard Deviation 4.13 X 10-*
Median 5.23 X 10-*
Geometric Standard Deviation 1.85
Q9 7 .5 9 7 .5 th Percentile 1.74 X 10-*
Q2 .5 2 .5 th Percentile 1.59 X 10-*
Qg7.5/Mean 2.8
Mean/Q2.5 3.9
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2aSE+03-|
u ia8E+03
i
OJKE+OO
22CE4Î7
Total Effective D o s e
Efectrfô Dose (Sv)
sjsee-os
Figure 4.5: Distribution of calculated propsective doses for inhalation of
2J37G#03
w 1.iœ#03
o.œe+00255E-07
15)ÜdlER€H3hA3[)0SK)
436E-.05
Effective Dose (Sv)
Figure 4.6: Distribution of calculated propsective doses for inhalation of
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4.3.2 Retrospective Dose Uncertainty
For the retrospective analysis first the distribution for the intake is calculated 
from the bioassay measurement. Then the effective dose is calculated using the 
distribution of intakes.
Table 4.8: Calculated distribution of the intake from a bioassay measurement 
following inhalation of (Bq)
Mean 3.26 x 10^
Standard Deviation 6.77 x 10^
Median 1.92 x 10^
Geometric Standard Deviation 2.55 
97.5th Percentile 1.31 x 10^
2.5th Percentile 3.29 x 10^
1.70EXM 1
oaoe*oo
EEsürneüedküzd#
3.29E+03 657E+03 
Intake (Bq)
1.31E+04
Figure 4.7: Distribution of intake from a bioassay measurement following inhala­
tion of
Figures 4.8 - 4.12 show the calculated retrospective doses for the three ura-
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Table 4.9: Uncertainty on retrospective dose calculation for inhalation of 
(Sv)
u_
Mean 2.22 x 10-^
Standard Deviation 3.42 X 10-2
Median 1.18 )< lC)-2
Geometric Standard Deviation 3.03
97.5th Percentile 9.78 X  10-2
2.5th Percentile 1.36 X 10-3
(597.5/-ATean 4.4
Mean/Q2.5 16.4
Total Bfective D ose
O.OOE+00
9.73E^
4Z]I==C3,.
7JB0E4Q
Effective Dose (Sv)
Figure 4.8: Distribution of calculated retrospective doses for inhalation of
Table 4.10: Calculated distribution of the intake from a bioassay measurement 
following inhalation of (Bq)
Mean 3.07 x 10^
Standard Deviation 4.91 x 10^
Median 1.84 x 10^
Geometric Standard Deviation 2.54 
97.5th Percentile 1.25 x 10^
2.5th Percentile 3.13 x 10^
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EEsümatedküzüoB
3.29E+03 657E+03 1J31E+04
Figure 4.9: Distribution of intake from a bioassay measurement following inhala­
tion of
Table 4.11: Uncertainty on retrospective dose calculation for inhalation of 
(Sv)
Mean 1.89 X  10-2
Standard Deviation 2.87 X  10-2
Median 1.02 X 10-2
Geometric Standard Deviation 2.98
97.5th Percentile 8.50 X 10-2
2.5th Percentile 1.18 X 10-3
Qgj,^/Mean 4.5
Mean/Q2.5 16.0
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T otal E ffective D o s e
6jZGE+(B
t, aiSEKB
324E434 1J84B01
Effective Dose (Sv)
3JG8E4M
Figure 4.10: Distribution of calculated retrospective doses for inhalation of ^^ (^7
Table 4.12: Calculated distribution of the intake from a bioassay measurement 
following inhalation of (Bq)
(Sv)
Mean 2.93 X 1Q3
Standard Deviation 3.58 X  1Q3
Median 1.88 X 1Q3
Geometric Standard Deviation 2.44
97.5th Percentile 1.16 X 10^
2.5th Percentile 3.21 X 1Q2
ertainty on retrospective dose calculation for ir
Mean 1.87 X 10-2
Standard Deviation 3.90 X 10-2
Median 1.00 X 10-2
Geometric Standard Deviation 3.03
97.5th Percentile 8.94 X  10-2
2.5th Percentile 1.18 X 10-3
Qgy.s/Mean 4.8
Mean/Q2.5 15.8
238U
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Figure 4.11: Distribution of intake from a bioassay measurement following in­
halation of
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Figure 4.12: Distribution of calculated retrospective doses for inhalation of
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nium isotopes. Tables 4.9 - 4.13 show the statistics for those distributions. The 
uncertainty factors seen for the retrospective dose calculations are significantly 
higher than those seen for the prospective dose calculations.
4.4 Conclusion
The uncertainty analysis presented here complements the analysis done by Puncher 
and Burt [Puncher and Burt, 2013] for calculating uranium doses to members of 
the public. The biokinetic parameters that were shown to have the largest effect 
on the calculated dose were assigned probability distributions to reflect the uncer­
tainty in each of the parameters. Where possible previous quantitative analyses 
have been used to derive the probability distributions however this is not possible 
for each of the parameters. Therefore some of the probability distributions reflect 
best scientific estimates of the uncertainty.
The uncertainty factors for prospective dose calculations for ingestion occu­
pational exposures to uranium was seen to be approximately 6. A narrower 
uncertainty factor of approximately 4 was seen for inhalation exposures. These 
results along with the analysis by Puncher and Burt for public exposures to ura­
nium suggest that significant uncertainty remains in the calculation of radiation 
doses from uranium exposures. Therefore a precautionary approach should be 
adopted on the risks from internal exposures to uranium.
For the retrospective analysis the uncertainty factors were significantly larger 
than for the prospective analysis. This is expected as the uncertainties in the 
biokinetic model parameters are magnified by being applied to calculate the in­
take first and then the dose. Any assessment of effective dose from bioassay
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measurement will therefore have a large associated uncertainty (more than a fac­
tor of 10).
92
Chapter 5 
A Bayesian M ethod For 
Identifying Occupational Intakes 
For Uranium Workers
The results in chapter 4 demonstrated that significant uncertainty is present 
on the calculation of effective dose. This is true for prospective calculations 
and is particularly pronounced for retrospective dose estimates. In the nuclear 
industry it is common for people working with uranium compounds to have to 
provide routine bioassay samples (urine and faecal samples) to confirm that the 
control measures to prevent intakes are working correctly. In this chapter a novel 
Bayesian technique is developed for interpreting bioassay data that could be used 
for determining whether an intake has occurred or not.
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5.1 Introduction
Measuring the uranium activity content of urine is an important bioassay tech­
nique for checking whether an occupational intake of uranium has occurred. How­
ever, this process can be confounded by environmental uranium that will always 
be present in the bioassay sample. This activity results from excretion of natu­
ral uranium that was originally ingested in food and drinking water [WHO, 2005]. 
Distinguishing occupational intakes of uranium from environmental intakes is im­
portant so that resources are not wasted investigating false positive results and 
to maintain confidence in the internal dosimetry programme.
One approach for distinguishing occupational and environmental intakes of 
uranium is to compare the monitoring result against a decision level that has been 
determined from a distribution of measurements of uranium in urine obtained 
from a non-occupationally exposed population. Nicholas and Bingham [Nicholas 
and Bingham, 2011] discuss how the issue of environmental uranium content in 
bioassay sampling is currently addressed at the Atomic Weapons Establishment 
(AWE). For cases where enriched or depleted uranium is known to be the only 
internal hazard, then the isotopic ratios of the uranium in the bioassay samples 
is used to infer an exposure. However, for potential worker exposures to natural 
uranium, a decision level is set for total uranium activity; if the measured value 
exceeds this limit then additional measurements are taken to confirm an intake 
occurred and to estimate the dose.
This decision level is derived from a distribution of measurements of uranium 
in urine obtained from a population of adults who only had environmental intakes 
of uranium and is chosen so that the probability of observing a value greater than
94
Chapter 5
it is judged too small to be the result of an environmental intake alone. In this 
regard, it is akin to the classical P-value used in classical statistical inference, 
and the distribution from which it is derived is the classical null distribution. In 
this framework the null and alternative hypotheses are defined as follows:
N ull H ypothesis ( H q)
The measurement represents natural uranium that is excreted following 
ingestion of natural uranium in food and water.
A lternative H ypothesis ( Hi )
The measurement represents natural uranium that is excreted following 
occupational exposure via inhalation and ingestion of natural uranium in 
food and water
For the bioassay program at AWE the decision level is set at 2.5 mBq of 
uranium activity excreted in urine per day.
A drawback of this classical approach is that is does not include any infor­
mation about the potential occupational exposure that can help infer whether 
an occupational intake has actually occurred; in other words it accounts for in­
formation regarding the null hypothesis but not the alternative hypothesis. In 
particular it does not address:
1. The likelihood that an occupational intake might occur during the monitor­
ing interval. If occupational intakes are rare, then not accounting for this 
can lead to an unexpected frequency of false positive results (inferring an 
occupational intake occurred when in fact it did not)[Miller et ah, 2002].
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2. The range and magnitude of the possible occupational intakes. This will 
affect the magnitude of the measurement and therefore the reliability of 
the classical decision level. For instance, if the measurements resulting 
from typical occupational intakes are very low (because, say, intakes are 
very low) compared with the decision level, this again will lead to a high 
incidence of false positives.
3. The influence of biokinetic parameter values, and their uncertainties, which 
relate occupational intakes to the amount of uranium predicted in urine; 
this can have the same effect as (1).
Bayesian methods provide a useful framework for incorporating such addi­
tional sources of information to distinguish and quantify occupational intakes 
from natural background activity. For example Miller et al [Miller et al., 2008] 
demonstrated the advantages of the Bayesian method over traditional statis­
tical approaches to internal dosimetry for identifying intakes of plutonium at 
Los Alamos National Laboratory (LANL). The Bayesian approach developed by 
Miller et al uses a computational algorithm based on MCMC methods .
An alternative to using MCMC for Bayesian analysis is the Weighted Likeli­
hood Sampling Method (WeLMoS) [Puncher and Birchall, 2008]. In this approach, 
parameters are sampled from defined prior distributions and weighted according 
to how well they describe the data (weighted by the likelihood density). The 
method has been shown to perform well when calculating Bayesian uncertainties 
on biokinetic parameters and doses in cases where bioassay data are not overly 
informative , and so the method is well suited to the analysis of typical occupa­
tional bioassay data. However, the method has not been applied to distinguish
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true occupational intakes from background environmental intakes in a Bayesian 
hypothesis testing framework.
This chapter addresses the following:
• Describes a Bayesian hypothesis testing framework for identifying and quan­
tifying occupational intakes of uranium from measurements of uranium in 
urine bioassay.
• Evaluates the method by applying it to a bioassay regime used at AWE.
• Investigates the effect of the uncertainty on intake, lung solubility parame­
ters and the prior probabilities of the competing hypotheses, on the outcome 
of the test.
• Discusses the implications of results for routine monitoring of uranium and 
the classical decision level used at AWE.
5.1.1 The M ethod
Bayesian hypothesis testing is an inference technique for comparing the probabil­
ity of hypotheses given a common set of data. The probability of each hypothesis 
given the data is evaluated and the ratio of the probabilities used to infer which 
of the two hypotheses is favoured by the data.
As noted above, for a particular measurement of uranium activity in a col­
lected urine sample, there are two significant hypotheses which can explain the 
presence of uranium:
Hq Environmental Intake Only
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Hi Environmental plus Occupational Intake
( . . )
By definition:
P( M)  =  Y ,  X P{M\Hk)  (5.2)
fc=0,l
Where:
P{Hk\M)  is read as the probability of Hk given M  and is called the posterior 
probability
P{M\Hk)  is the likelihood function. It is the probability of observing the mea­
surement M, given hypotheses H^
P{Hk) is the prior probability of hypothesis Hk
P { M)  is the total probability of observing measurement, M
In the present context, the prior, P{Hk) for each hypothesis is given by:
P(7fo) =1 -  f  (Ifi) (5.3)
P{Hi) =P(EnvironmentalIntakeOccurred) x P{OccupationalIntakeOccurred)
(5.4)
Note that, because it is reasonable to assume that environmental intakes of
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uranium always occur, the prior probability, P{Hi), is given by:
P{Hi) =  IxPiOccupationall ntakeOccur red) = P  {Occupational I  ntakeOccur red)
(5.5)
For each hypothesis there is an uncertain intake parameter, Ik, that has a 
direct effect on the calculation of the likelihood, P{M\Hk).  In the case of a single 
measurement, where lognormal measurement uncertainties errors are assumed, 
the likelihood is of the form:
Where:
M  Measured uranium in urine {Bq.day~^)
Ik The intake pertaining to hypothesis k. For the alternative hypothesis this is 
actually a mixture of intakes (discussed below)
Bk{t) Uranium in urine content {Bq.day~^) predicted by the biokinetic model 
associated with hypothesis, Hk, at the time of measurement, t.
Œg Measurement geometric standard deviation.
The likelihood of each hypothesis, P{M\Hk),  is calculated by integrating out 
all of the possible intake values, represented by the distribution, P{Ik\Hk)HIk 
associated with the hypothesis as follows:
P{M\H„) = j  P{M\h,H^)P{h\Hu)dh  (5.7)
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The posterior probability for each hypothesis is therefore given by:
I  P (M \h ,  H ,)P {h \H ,)dh  X  P(H,)
P(H,\M) p ^ H j ) x J P { M \h ,H j ) P { h \ H j ) d h  ( - ^
j=0,l
Where A; =  0 or 1.
This chapter considers an uncertainty distribution on the intake only. Thus, 
to calculate the marginal likelihood of each hypothesis, prior probability dis­
tributions for the intake parameter of each hypothesis, P{I\Hk), are required. 
However, Equation 5.7 can be readily extended to include uncertainties in other 
parameters including those in the biokinetic model and intake regime. More 
formally, this extension solves the following integral:
P (M |% ) =  j  P{M\Ik,L,Hk)P{Ik,L\H,)dh.dL  (5.9)
Where L is a vector of model parameter values.
5.1.1.1 O btaining an estim ate  of th e  occupational intake
If the alternative hypothesis is concluded to be true after the test has been per­
formed, then an estimate of the occupational intake can be obtained from the pos­
terior distribution, P{Iocc\M,Hi); for example the expectation of I (the mean) 
is given by:
< / > = J  P { I k \ M , H ^ ) . h . d h  (5.10)
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5.1.2 Deriving Prior D istributions for Intakes
For hypothesis Hq, the intake parameter, Iq, is equal to the environmental intake 
lenv' For the monitoring program at AWE, the distribution of environmental 
intakes can be derived from bioassay measurements reported by Nicholas and 
Bingham [Nicholas and Bingham, 2011] for a population that is not occupationally 
exposed to uranium. Personal communication with the authors suggests that this 
distribution can be described by a lognormal distribution with a median of 0.24 
mBq.day~^ and a geometric standard deviation of 1.6.
The measured activity in urine in the distribution can be converted into an 
environmental intake or intake rate by applying a biokinetic model and assumed 
pattern of intake that relates the measurement M, to the intake I, using an 
appropriate function, B{t), which predicts the measurement in urine at time, t:
The measured distribution of activity in urine for the population is therefore 
scaled by a factor of B{t) to convert it into a prior probability distribution of 
environmental intakes. The function B{t) represents the biological processes that 
describe the retention and excretion of uranium following ingestion (the biokinetic 
model), and also accounts for the pattern of intake; for environmental intakes this 
is likely a constant daily chronic rate of intake.
This process of converting the bioassay measurements into a distribution of en­
vironmental intakes potentially contributes additional uncertainty to the hypothe­
sis test as it is not known whether the correct assumptions model are being used to 
transform the measurement into an intake. The uncertainty is removed however.
1 0 1
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because to calculate P{M\I ,  Hk) to obtain the marginal likelihood P{M\Hk),  the 
sampled intake is converted back to the corresponding measurement using the 
same function B{t), in equation 5.6. Therefore, because we are only interested in 
the marginal likelihood, P{M\Ho),  and not the actual intakes and doses resulting 
from environmental intakes of uranium, the test is independent of the choice of 
biokinetic model used to construct the intake prior for environmental intakes from 
the environmental measurement data. This removes a significant uncertainty in 
the hypothesis test. In this chapter, the factor B{t) is simply assumed to be 
unity, and thus the prior distribution of environmental intakes is assumed to be 
the distribution of measurements from by Nicholas and Bingham.
Hence the likelihood for hypothesis Hq for each sampled intake value is simply:
- 1—
Where Menv =  hnvBenv{i) IS a measurement of natural uranium in urine 
sampled from the distribution from Nicholas and Bingham.
For hypothesis Hi, however, the intake parameter is a mixture of an occu­
pational and an environmental intake, represented as a joint prior distribution, 
P{Iocc, Ienv)‘ The environmental and occupational intake components have dif­
ferent bioassay functions and therefore the likelihood for this hypothesis is:
D/' 7\ / f l r  TT \ ^ )  ln {Ie n y .B e n v { l ' )  p  Iocc 'B occ{t) )
^  ~ MV2iln{af ^  1 ^
(5.13)
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In contrast to the environmental intake component, Menu, there is no equiv­
alent data set that can be used to precisely derive a prior distribution for the 
occupational intakes, Iqcc- Therefore the likelihood calculation for this hypoth­
esis is not independent of the choice of biokinetic model for the occupational 
intake. Indeed, because the outcome of the test is closely dependent on the mea­
surement prediction, /occ-^occ(A), it is dependent on the assumed occupational 
exposure pathway: pattern of intake, biokinetic model, model parameter values 
and intakes. It is therefore important that these parameters are estimated as 
accurately as possible to avoid bias.
In this study, the prior distribution for occupational intakes was represented 
by a broad lognormal distribution with a geometric standard deviation of 4 and 
a median value of 50 Bq per year. This prior was based on published personal 
air sampler data that showed that a broad lognormal distribution is a reason­
able representation for occupational exposures [Stevens, 1989]. It is worth noting 
that occupational exposures have reduced significantly in the nuclear industry 
since the analysis by Stevens. To apply the described Bayesian method to a 
specific monitoring regime it would be worthwhile generating a specific prior on 
occupational intake for the population of interest.
5.1.3 H ypothesis Ratio and Bayes Factors
In addition to the prior distributions for the occupational and environmental 
intakes, the full Bayesian analysis requires that prior probabilities are specified 
for each of the two hypotheses. Where no information is available to favour 
one hypothesis over another, the probability of each either hypothesis can be
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assumed to be equal. Therefore, for this analysis here it was initially assumed 
that the prior probability for either hypothesis, P{Hk), is the same. Under these 
conditions the hypothesis test is simply therefore a measure of the ratio of the 
marginal likelihoods of the data, M, given each hypotheses for the two hypotheses 
given a particular measurement. This ratio is also called the Bayes factor, B F  
and is calculated as follows.
JP{M\I,Ho)P{I\Ho)dI
JP(M \I ,H ,)P(I \HQ dI   ^  ^ ^
Kass and Rafferty[Kass and Raftery, 1993] proposed the decision criteria in 
table 5.1 to decide whether the evidence against the null initial hypothesis Hq is 
significant.
Table 5.1: Decision criteria for hypothesis testing
Evidence against Hq
0-5 Positive
5-10 Strong
>10 Decisive
The decision criteria set out in table 5.1 is on the same scale as the likelihood 
ratio test used in classical statistics and is therefore useful when comparing the 
classical decision level used in a uranium bioassay monitoring programme to that 
given by the Bayesian hypothesis test. The implications of assuming that the prior 
probabilities on each hypothesis are equal are discussed later in this chapter.
5.1.3.1 Using the W ELM OS m ethod for Bayesian H ypothesis Testing
A new computer program was written by the author to apply the Bayesian hy­
pothesis test for a given measurement of uranium in urine. The code implements
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an adaptation of the WeLMoS method to calculate the marginal likelihood for 
each hypothesis. This method is similar to the WeLMoS method except that the 
intake is sampled from its prior distribution using the Latin hyper-cube method 
described by McKay et al[McKay et ah, 1979] as it is implemented by Puncher 
and Birchall [Puncher and Birchall, 2008], rather than sampling the intakes (with­
out replacement) from a uniform distribution and weighting the likelihood by the 
prior probability density of the intake, as described by Puncher and Birchall. The 
software tool IMBA is used to solve the biokinetic models.
The code performs the following steps:
1. The model parameters (uranium material type and monitoring regime) for 
calculating the estimated bioassay measurement for a given occupational 
intake are set in IMBA. For unknown uranium compounds the ICRP pub­
lication 68 inhalation parameter values (with absorption Type M), and the 
ICRP publication 69 model for uranium are assumed.
2. An occupational and environmental intake are sampled independently from 
their prior distributions. For the latter, this entails simply sampling a mea­
surement value, Menv, from the distribution from Nicholas and Bingham. 
The occupational intake is sampled from a lognormal distribution with me­
dian of 50 Bq/y and GSD of 4. Sampling is performed using the Latin 
hyper-cube sampling regime described by Puncher and Birchall [Puncher 
and Birchall, 2008].
3. For the environmental intake hypothesis (Hq), the measurement of uranium 
in urine and the sample from the prior probability for environmental intakes 
are then used to calculate the likelihood, P(M |7, H q),  using equation 5.12.
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4. For the alternative hypothesis, Hi, the intake is a mixture of an occupa­
tional and environmental intake. The likelihood, P{M \I,H i) is calculated 
for the sampled environmental and occupational intakes using equation 5.13. 
The value, Boccif) is the bioassay prediction per unit intake calculated using 
the parameters set in step 1, with IMBA Professional Plus [Birchall et ah, 
2007].
5. Steps 2, 3 & 4 are repeated N times and the average likelihood is calcu­
lated from the sampled likelihoods for each hypothesis. For example, for 
hypothesis Hq the average likelihood is calculated using equation 5.15
i  Y  P { M \ I i , H o )  «  [ P ( M \ I , H o ) P { I \ H o ) d I  (5.15)
i= l , N
6. The marginal weighted likelihoods calculated for the two hypotheses in step 
5 are then used to calculate the Bayes factor for the bioassay measurement 
given.
JPiM \I,H o)P(I\H o)dI 
S  P {M \I,H ,)P {I\H ,)dI )
The decision criteria is then calculated.
Decision Criteria =  2 x ln{BF  ) (5.17)
Note that the above algorithm only samples for intakes; however, it can be 
extended to include uncertainties in other biokinetic parameters by including an 
outer loop that encompasses steps 1-5, where biokinetic parameter values are
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sampled from defined prior distributions before the model is solved by IMBA in 
step 1.
5.2 Applying the M ethod
5.2.1 Uranium monitoring at the Atom ic W eapons Estab­
lishment (AWE)
Because the environmental monitoring data relates to exposures at AWE [Nicholas 
and Bingham, 2011], the Bayesian method described above was applied to a 
bioassay regime for detecting uranium exposures at this facility. In this regime 
a 24 Hr urine sample is taken every 90 days and the total uranium activity in 
urine in the bioassay sample is compared to a decision level of 2.bmBq.day~^. If 
an occupational exposure is suspected (the measurement value is higher than the 
decision level), an acute intake by inhalation is assumed to have occurred at the 
mid-point of the sampling period.
Steps 1-6 were performed for a range of uranium in urine measurements to 
identify the measurement value for which the decision criteria calculated in step 6 
decisively favours an occupational intake. This measurement value was compared 
with the decision level used at AWE. The calculation was repeated for samples 
N of 100, 1000 and 10000, to monitor convergence.
For the initial analysis, the biokinetic model and parameter values used at 
AWE to estimate intake and doses from routine monitoring data were used, 
namely:
1. The HRTM in ICRP publication 66[ICRP, 1994].
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2. The ICRP Publication 69 systemic model for uranium [ICRP, 1995a].
3. A set of lung absorption parameter values, for brevity termed the U AWE 
absorption type. The values for the rapid fraction, jC, rapid dissolution 
rate, Sr, and the slow dissolution rate, Sg, are given in table 5.2.
The initial analysis assumed that the null and alternative hypotheses were 
equally probable. As discussed, there are uncertainties associated with these 
assumptions and other parameters that influence the outcome of the hypothesis 
test. The test was therefore repeated to investigate the effect of these.
5.2.1.1 The effect of Lung Solubility
Previous studies have shown that the values assumed for the lung absorption 
parameters strongly influence the amount of uranium in urine following inhala­
tion [Puncher et a l, 2013], and these will affect the outcome of the hypothesis 
test. To investigate the effect of the choice of lung solubility parameters on the 
hypothesis test, the calculations were repeated for a variety of materials and ICRP 
absorption types. The ICRP classifies the lung solubility of inhaled materials as 
Type F (fast rate of absorption to blood). Type M (medium rate of absorption 
to blood) or Type S (slow rate of absorption to blood). Specific solubility pa­
rameters have been estimated for some of the more common uranium compounds 
encountered in the nuclear industry, including at AWE. The Bayesian hypothesis 
test was repeated for each of the uranium material types shown in table 5.2, by 
setting the appropriate absorption parameter values in IMBA at step 1 of the 
calculation.
As discussed in chapter 3, there is significant uncertainty on the estimated
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Table 5.2: Uranium Material Types and Associated Lung Solubility Parameters
Material Type f r Sf
Type F 1 1 X 1 0 2 0
Type M 9 . 9 9 5 5  X 1 0 “ ^ 1 X 1 0 - 2 5  X 1 0 - 3
T ypes 9 . 9 8  X 1 0 “ ^ 1 .0 0 1  X 1Q2 1 X 1 0 - 1
U AWE 3  X 1 0 - 2 1 5  X 1 0 - 1
U O 2 Ceramic 8  X 1 0 - 3 1 .3 2 . 6  X  1 0 - 1
UTBP 9 . 7  X  1 0 - 1 1 .2  X  1 0 ' 2 .1  X  1 0 - 2
values of the lung absorption parameters for most uranium bearing materials. To 
explore the effect of this uncertainty, the hypothesis test was repeated for the 
material type U AWE with the long term retention parameter, Sg, varied by an 
order of magnitude above and below the given value. These represent plausible 
bounds for the 95% range of values of 5g for this material.
5.2.1.2 The effect o f the prior distribution o f on occupational intake
The occupational prior distribution on intakes was based on monitoring informa­
tion from another facility and there exists some uncertainty on whether it can 
be applied to a regime at AWE. To explore the sensitivity of the hypothesis test 
to the chosen prior distribution on occupational intakes, the hypothesis test was 
repeated with a flat prior bound between 0 Bq and 100 Bq. For situations where 
intakes of uranium larger than 100 Bq have occurred there are likely to be addi­
tional indicators that an exposure occurred of an exposure and this is therefore 
a reasonable upper bound for the prior distribution for routine monitoring where 
no intake is suspected.
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5.2.1.3 The effect of the prior probabilities on hypotheses
In calculating the Bayes Factor and decision criteria, it has been assumed that 
the prior probabilities of the two hypotheses, P{Hq) and P(i^i), are the same. 
However, in modern facilities it is very likely that for routine monitoring, where 
there has been no indication of an exposure from other monitoring data i.e. air 
sampling, nose blow or contamination monitoring, the prior probability of an 
intake having occurred should be significantly less than the probability that the 
measurement results from for an environmental intake only; in other words:
f  (^ i) «  (5.18)
Little et al[Little et al., 2003] proposed an occupational uranium intake proba­
bility per year of 0.01 for the facilities they were studying. This intake probability 
relates to an individual’s chance of having an occupational intake in a year. Ap­
plying the same probability of an intake occurring here then the prior probabilities 
for the two hypotheses are; P{Hi) =  0.0025 and P{Hq) = 0.9975 for a 90 day 
each monitoring period. With values for the probabilities of the hypothesis priors 
defined, the ratio of the probabilities can be calculated directly.
P(gp|M) /P (M |7 , Ho)P{I\Ho)dI X P{Hq)
P{H^\M) /P (M |7 ,i? i)P ( / |P i)d /x P (iif i )   ^ ' ’
Under these conditions, the decision criteria defined by Kass and Rafferty [Kass 
and Raftery, 1993] is no longer required as the ratio of the probabilities for the 
hypotheses can be calculated. Therefore the decision level where an occupa­
tional intake is the favoured hypothesis occurs when the posterior probability of
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P{Hi \M)  > P{Ho\M).
5.3 Results
The results of applying the method to the monitoring regime at AWE are sum­
marised in table 5.3. This shows the decision level calculated for N=100, 1000 
and 10000 iterations of the code.
Table 5.3: Calculated decision level for AWE bioassay regime
Number of iterations
 100 1000 10000
Decision level {mBq.day~^^ Z5 2^ 6 270
The calculated decision level for the AWE bioassay regime was similar to the 
classically derived decision level that is used at that facility. Convergence of the 
calculated decision level occurred for relatively few iterations (~1000), taking 
only a few minutes on a fast workstation.
5.3.1 The effect of lung solubility
Table 5.4 summarises the results of the Bayesian hypothesis test when different 
uranium material absorption types are assumed.
As can be seen in table 5.4, the majority of the calculated decision levels 
are similar to the value used at AWE. Type S material is the exception with a 
higher bioassay measurement being required in order for the occupational intake 
to become the favoured hypothesis. The change in the decision level for the U 
AWE material that results from uncertainty in the value of the slow dissolution 
rate, Ss is shown in table 5.5.
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Table 5.4: Decision level for discrete uranium material types
Measurement (mBq.day~^) 
Uranium Material Decision Level
(evidence of an intake)
Strong Decisive
Classical Decision Level - 25
Type F 1.5 2.4
Type M 1.4 2.3
Type S 2.0 4.0
UTBP 1.3 2.3
U AWE 1.3 2.6
UO2 (Ceramic) 1.4 2.7
Table 5.5: Decisive decision levels for material type U AWE with a range of 
plausible values for
Uranium Material Decision Level mBq.day ^
U AWE 2 . 6
U AWE (gg X  10) 2 . 2
U AWE (gg /  10) 3.5
When the value of Ss for U AWE was reduced to the lowest plausible value, 
the decision level approaches that determined for a Type S material. In contrast, 
increasing the value of Sg by a factor of 10 has much less of an effect.
5.3.2 The effect of the prior on occupational intake
The decision level calculated using the uniform distribution was 2.0 mBq.day~^, 
which is lower than the decision level of 2.6 mBq.day~^ calculated using the 
lognormal prior distribution on occupational intake.
When the median on the prior on the occupational intake is multiplied by 10 
the decision level increases to 3.2 mBq.day~^. When the median on the occupa­
tional intake is divided by 10 the decision level decreases to 2.4 mBq.day~^.
112
Chapter 5
5.3.3 The effect of the prior probability of an occupational 
intake occurring
This test was applied to the bioassay regime at AWE assuming P(i7i)=0.0025 
and the absorption parameter values of material type U AWE. This showed that, 
reducing the prior probability of the alternative hypothesis by a factor of 200 
gave a decision level of 3.2 mBq.day~^.
5.4 Discussion
The work described here derives a simple Bayesian hypothesis testing method 
that can identify, and then quantify, occupational intakes of uranium in a urine 
sample that also contains activity resulting from background intakes of environ­
mental uranium. The test uses a modified version of the WeLMoS method, and 
appears to perform well, with relatively few iterations required (1 x 10 )^ for the al­
gorithm to converge. This compares favourably with more advanced integration 
methods such as MCMC; however, the modified WeLMoS method is generally 
not as efiicient as MCMC and may perform less well when scaled up to deal with 
multiple monitoring intervals if it is applied in an ongoing routine monitoring 
program.
Little et al[Little et al., 2003] applied the MCMC Bayesian hypothesis test 
method developed by Miller et al [Miller et al., 2002] to the interpretation of 
uranium bioassay monitoring at LANL. Initially an attempt was made to use 
data collected on the uranium levels in the local drinking water to provide a prior 
probability distribution on environmental intakes for the workforce. This method
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was not successful however, due to the observed weak correlation between dietary 
intakes of uranium and excretion rates.
An alternative technique was proposed by Little et al [Little et a l, 2007] that 
used the base line excretion rate for each individual from previous monitoring 
results as a prior probability on background intakes (environmental combined 
with previous occupational exposures) specific to that individual. This method 
is satisfactory for the assessment of each individual but may not be appropriate 
for setting a decision level for the whole monitoring programme. On the other 
hand, it does take account of an individuals environmental intakes and any pre­
vious occupational exposures, and therefore is suitable for an individual worker’s 
ongoing monitoring program.
The method developed here established the environmental intake prior distri­
bution directly from the bioassay measurement of non exposed individuals. This 
prior distribution is applicable to the population as a whole and removes the 
uncertainty inherent in the correlation between the environmental intake and the 
excreted uranium.
The modified WeLMoS Bayesian hypothesis test was applied to a single rou­
tine monitoring interval for a bioassay regime used at AWE for the assessment 
of uranium intakes. Good agreement was observed between the classically de­
rived decision level (2.5 mBq.day~^) and the decision level calculated using the 
Bayesian hypothesis test (2.6 mBq.day~^) in its basic configuration. However, 
this is perhaps unsurprising because, in its basic form, the Bayesian test is es­
sentially the same as the classical test: it assumes that the null and alternative 
hypothesis is equally probable, and thus, like the classically derived decision level, 
inference is based solely on the likelihood function. Nevertheless, it provides a
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useful framework to assess the effect of different exposure parameters that are 
not considered in deriving the classical decision level.
In this chapter, the effect of the assumed rate of absorption from the lungs to 
blood and the (prior) probability that occupational intakes occur are considered. 
The results show that:
Rate of absorption
If the material is assumed to be relatively soluble in the lung, then the 
Bayesian decision level is close to the classical value of 2.5. However, the 
Bayesian derived level is significantly higher when the material is assumed 
to be insoluble. This means of course that if the material workers are actu­
ally exposed to is insoluble, but the classical decision level is used (or the 
Bayesian approach is applied but the material is assumed to be soluble) 
then this will result in a significant number of false positives workers being 
identified as having an occupational intake when they in fact did not. It 
will also mean that doses for workers who did have intakes will be under­
estimated if the material is assumed to be more soluble than it actually 
is. This result is all the more significant because the rate of lung absorp­
tion of many uranium bearing materials is uncertain. This is illustrated by 
the sensitivity analysis where the material U AWE is considered to be less 
soluble than the nominal values assigned to it.
The prior probability of an occupational intake occurring
In modern nuclear facilities, effective controls are in place to minimize ex­
posure to airborne radionuclides and ensure that occupational intakes of 
uranium materials by inhalation are very unlikely. This situation is mod-
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elled in this thesis by assuming a prior that is adapted from one described 
by Little et al [Little et al., 2003]. The prior assumes that the probability of 
an occupational intake occurring (P(L7i)=0.0025) is 200 times lower than 
assumed in the baseline test (P(LTi)=0.5), where the alternative and null 
hypothesis are assumed to be equally probable. The results show that this 
change in the prior results in a relatively modest increase in the decision 
level from 2.5 mBq.day~^ to 3.2 mBq.day~^. This increase in the decision 
level is due to the reduction in the occupational intake prior probability 
leading to a larger likelihood being required before an occupational intake 
is favoured by the hypothesis test. If all other parameters in the test are 
assumed to be accurate, including the absorption parameter values of the 
U AWE material, and the prior on occupational intake, P (/i), then the re­
sults suggest that this increase would prevent a significant number of false 
positive results. Indeed, if the prior adapted from Little et al [Little et al., 
2007] is considered to reasonably represent the frequency of occupational 
intakes at AWE, then it suggests that assuming the classical decision level 
would mean that on average 74% of workers would be reported as having 
an intake that did not occur (they would be false positives). Of course, the 
prior derived from Little et al [Little et al., 2007] is a nominal one, included 
to assess the method, and there are other biokinetic uncertainties that af­
fect the result. Nevertheless, it seems reasonable to assume that the actual 
prior should have a value of P(LTi) <<  0.5, suggesting that the classical 
decision level would be unduly conservative if used as a rigorous control 
value, especially as occupational intakes at AWE are thought rarely to oc­
cur. Nicholas and Bingham [Nicholas and Bingham, 2011] acknowledge that
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the value is only used to indicate a potential exposure at AWE.
5.5 Conclusion
The Bayesian hypothesis testing method described here is relatively simple and 
converges quickly. The method avoids having to do a background correction of 
uranium by incorporating measurements of uranium in urine, that result from 
environmental intakes, directly into the likelihood function. The test, which con­
siders only a single monitoring interval, is used to identify exposure parameters 
that affect the reliability of a classically derived decision level in detecting occupa­
tional intakes of uranium during routine monitoring at AWE. This shows that the 
assumed lung solubility of the material and the likely frequency of occupational 
intakes affect the decision level. For the latter, the results show that the classical 
decision level results in too many false positives and would therefore be unduly 
conservative if used as a rigorous control. To address this, the Bayesian approach 
described here could be scaled up to deal with multiple monitoring regimes as 
part of an ongoing monitoring regime at that facility.
The developed Bayesian technique deals with the uncertainties involved in de­
termining whether an intake of uranium has occurred in a unified way. Significant 
uncertainty still remains on whether an intake has occurred and coupled with the 
uncertainty estimates derived in chapter 4 suggests a precautionary approach to 
preventing intakes of uranium is still valid for radiation protection.
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Conclusions
The aim of this thesis was to explore the uncertainty in the ICRP methodology for 
determining radiation doses from intakes of uranium isotopes. There were three 
areas identified where a contribution to the understanding of the uncertainties in 
uranium dose assessments could be made. These were:
1. Obtaining the best estimates for the model parameters used for calculating 
internal doses from uranium.
2. Estimating the uncertainty in the dose coefficient for occupational exposures 
to uranium.
3. Applying Bayesian techniques to the practical problem of identifying when 
occupational intakes of uranium have occurred and estimating doses from 
bioassay measurements.
In chapter 2 the sensitivity analysis confirmed that the important biokinetic 
parameters for intakes of uranium via inhalation were the lung solubility pa­
rameters. As the lungs are the most sensitive organ to ionising radiation it is 
reasonable that the parameters that describe how long the uranium will remain
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in the lungs are important for parameters for the calculation of the dose. This 
result is similar to those seen for other alpha emitting radionuclides. This guided 
the research towards obtaining best estimates for the lung solubility parameters.
In chapter 3 historical bioassay results from uranium exposures were used to 
derive distributions for the key solubility parameters. The novel joint analysis 
of the cases demonstrated the power of combining bioassay data and also how 
results from uranium monitoring programmes can be used to derive best esti­
mates for biokinetic parameters. These estimates may prove useful for future 
epidemiological studies into uranium exposures.
In chapter 4 the uncertainty on the effective dose for uranium exposures to 
workers in the nuclear industry were assessed using the derived probability dis­
tributions for the key biokinetic parameters. The uncertainty on the biokinetic 
model parameters for uranium is relatively high compared with other radionu­
clides as they cannot be easily tracked in the body following an intake. An assess­
ment of the uncertainty for both prospective and retrospective dose assessments 
was made. It was seen that the uncertainty on the retrospective dose assessment 
was significantly greater due to the biokinetic models being applied twice to the 
calculation.
In chapter 5 a novel Bayesian hypothesis test was developed in an attempt 
to improve the techniques used for determining when an intake has occurred 
from a bioassay measurement. This technique proved effective in integrating the 
natural background due to environmental intakes of uranium into the analysis. 
In its basic form where only the intake uncertainties were considered there were 
no significant advantages to be gained from using this Bayesian approach for 
most chemical forms of uranium . Discrete parameter sensitivity calculations
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were undertaken that demonstrated the importance of these parameters on the 
hypothesis test. To be a useful technique the uncertainty of the key biokinetic 
parameters would need to be included in the analysis.
The Bayesian approach should be applied to more uses in practical radiation 
protection as it provides a consistent method for integrating all the uncertainties 
that are inherent in any health physics measurement. Miller et al [Miller et al., 
2002] and Puncher and Birchall[Puncher and Birchall, 2008] have developed ef­
fective Bayesian techniques for internal dosimetry problems. The principles of 
Bayesian techniques however could be applied widely in the field of health physics.
The work in each of the chapters has shown that the analysis are heavily 
dependent on the (prior) probability distributions derived.
6.1 The prior probability distribution problem
The prior probability distributions for the biokinetic parameters are intended 
to describe the uncertainty on each of the parameters. This uncertainty should 
encapsulate the lack of knowledge on the mean value for the population of interest. 
It is however difficult to disentangle the natural variability in the population with 
the uncertainty in the population mean. This is a rather subtle but important 
difference as in a radiation protection system where a reference man is used, it 
would not be reasonable to design a system to protect smalls groups of people 
that are on the extremes for particular biokinetic parameters.
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6.2 Uncertainty on effective doses
The uncertainties on effective dose coefficients due to the uncertainty in the bioki­
netic parameters was seen to be significant for occupational intakes of uranium. 
Furthermore the uncertainties considered in this thesis exclude a number of other 
factors that could have a significant effect on the overall uncertainty on the effec­
tive dose coefficient. The ICRP radiation protection system has some inherent 
conservatism and the results of this uncertainty analysis demonstrate why this 
is required. While the risks for large (>100 mCy) external exposures are well 
known, progress is still required to determine with more certainty the risks from 
internal radiation doses.
6.3 Future developments
The techniques used here for deriving best estimates of the biokinetic parameters 
should be apphed to a wider range of bioassay results. Combining the bioassay 
results using a Bayesian approach was seen to narrow the uncertainty on the 
important biokinetic parameters. The probability distributions of the lung dis­
solution parameters derived here may be useful for radiation protection and for 
reconstructing doses in future epidemiological studies of uranium workers.
In practical radiation protection it is frequently the case that decisions are 
made based on sparse information where including prior information on the other 
factors that may infiuence the decision would be of benefit. The Bayesian tech­
niques used and developed here could be readily applied to the fields of radioactive 
waste sentencing or practical radiation monitoring and would provide a logical
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framework for decision making in radiation protection.
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